STOCK TITAN

Rockwell Medical agrees to $125M base-price acquisition

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Rockwell Medical, Inc. (RMTI) reported third-quarter net sales of $19.122 million, up 20% from $15.927 million a year earlier. For the first nine months of 2026, sales rose 7% to $54.238 million and gross profit rose 18% to $9.251 million; operating loss widened 11% to $4.762 million, and net loss was $5.101 million versus $4.760 million. Operating cash flow was $0.387 million, compared with $2.950 million used a year earlier. As of September 30, 2026, cash, cash equivalents and investments totaled approximately $22.5 million. Management believes it has sufficient funds for operating needs for at least 12 months; that assessment excludes the proposed acquisition.

After quarter-end, on November 2, 2026, Rockwell agreed to acquire Vantive Limited’s hemodialysis concentrates, machines, water-treatment systems, related consumables and technical-services business for a $125.0 million base price, subject to adjustments. Expected financing includes $100.0 million in seller term loans and a $25.0 million convertible note, plus up to $45.0 million contingent on revenue and EBITDA milestones. Seller financing takes effect at closing and does not fund pre-closing operations or transaction expenses. Closing is expected in mid-2027, subject to closing conditions.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month net sales rose 7% to $54.238 million.
  • Moderate pointNine-month gross profit rose 18% to $9.251 million.
  • Moderate pointNine-month operating cash flow was $0.387 million, versus $2.950 million used.

Negative

  • Moderate pointNine-month operating loss widened 11% to $4.762 million.
  • Moderate pointNine-month net loss was $5.101 million, versus $4.760 million.

Filing Explained

The remaining 13.1 million dollars in the ATM is not committed cash; acquisition-related financial filings may restrict access until required statements are filed.

The Vantive acquisition remains subject to closing conditions; its $25 million seller note is convertible into common shares, with aggregate issuances capped at 19.99% of pre-agreement shares or voting power unless stockholders approve more.

The note matures six years after closing and bears 3.0% annual interest payable in kind. Its initial conversion price is $14.94 per share and increases with that interest, so the interest does not add shares for the original principal.

As of September 30, 2026, the existing Innovatus term loans had a $9.1 million balance net of issuance costs, discounts and premiums; at closing, Rockwell must repay them in full with the Final Fee. The seller loans will be secured by liens on substantially all assets of Rockwell and its domestic subsidiaries.

An at-the-market facility allows gradual share sales at prevailing market prices; Rockwell reports $13.1 million remains, but says the acquisition may limit its use until required historical financial statements and pro forma information are filed, so it is not committed or immediately available funding.

Third-quarter net sales $19.122 million vs $15.927 million; 20% increase Three months ended September 30, 2026 vs 2025
Nine-month net sales $54.238 million vs $50.912 million; 7% increase Nine months ended September 30, 2026 vs 2025
Nine-month gross profit $9.251 million vs $7.817 million; 18% increase Nine months ended September 30, 2026 vs 2025
Nine-month operating loss $4.762 million vs $4.293 million; 11% increase in loss Nine months ended September 30, 2026 vs 2025
Nine-month net loss $5.101 million vs $4.760 million Nine months ended September 30, 2026 vs 2025
Nine-month operating cash flow $0.387 million provided vs $2.950 million used Nine months ended September 30, 2026 vs 2025
Cash, cash equivalents and investments Approximately $22.5 million As of September 30, 2026
Proposed acquisition consideration $125.0 million base purchase price; up to $45.0 million contingent consideration Vantive transaction; base price subject to adjustments and contingent payments tied to milestones
contingent consideration financial
"contingent consideration of up to $45.0 million"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.
convertible note financial
"a $25.0 million convertible note to be issued to an affiliate of Vantive"
A convertible note is a type of loan that a company gets from investors, which can later be turned into company shares instead of being paid back in cash. It matters because it helps startups raise money quickly without setting a fixed value for the company right away, making it easier to grow and attract investors.
Term SOFR financial
"bear interest at Term SOFR plus initial margins of 5.50% and 7.00%"
Term SOFR is a benchmark interest rate that reflects the cost of borrowing money over a specific period, based on actual transactions in the financial markets. It is used by lenders and borrowers to set the interest rates on loans and financial contracts, helping to ensure rates are fair and transparent. For investors, understanding term SOFR helps gauge borrowing costs and the overall direction of interest rates in the economy.
paid in kind financial
"2.00% of the interest due ... may be paid in-kind"
Paid in kind means a borrower or issuer settles interest or dividend obligations by issuing more securities (like extra bonds or shares) instead of paying cash. For investors this matters because it preserves the issuer’s cash but increases the number of securities outstanding, which can raise risk of dilution and change the effective return — like taking more coupons on an ongoing purchase instead of paying with money now.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were RMTI's third-quarter 2026 sales?

RMTI reported net sales of $19.122 million for the three months ended September 30, 2026, compared with $15.927 million in the same period of 2025, a 20% increase.

What is the price and financing for RMTI's proposed Vantive acquisition?

The proposed acquisition has a $125.0 million base purchase price, subject to customary working capital and other purchase price adjustments. Expected financing includes two seller-provided term loans totaling $100.0 million and a $25.0 million convertible note. The agreement also provides for up to $45.0 million in contingent consideration tied to revenue and EBITDA milestones.

When is RMTI's proposed Vantive acquisition expected to close?

The acquisition is expected to close in mid-2027, subject to customary closing conditions, including regulatory approvals, delivery of specified audited financial statements and completion of specified separation activities. The agreement sets an outside date of November 1, 2027, subject to extension in specified circumstances.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001041024false12-312026Q39/30/20260.100.10P1YP7DP8YP5Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purermti:segmentrmti:agreementrmti:tradingDayutr:sqftrmti:paymentrmti:loan00010410242026-01-012026-09-3000010410242026-11-0900010410242026-09-3000010410242025-12-3100010410242026-07-012026-09-3000010410242025-07-012025-09-3000010410242025-01-012025-09-300001041024us-gaap:PreferredStockMember2025-12-310001041024us-gaap:CommonStockMember2025-12-310001041024us-gaap:AdditionalPaidInCapitalMember2025-12-310001041024us-gaap:RetainedEarningsMember2025-12-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001041024us-gaap:RetainedEarningsMember2026-01-012026-03-3100010410242026-01-012026-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001041024us-gaap:CommonStockMember2026-01-012026-03-310001041024us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001041024us-gaap:PreferredStockMember2026-03-310001041024us-gaap:CommonStockMember2026-03-310001041024us-gaap:AdditionalPaidInCapitalMember2026-03-310001041024us-gaap:RetainedEarningsMember2026-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-3100010410242026-03-310001041024us-gaap:RetainedEarningsMember2026-04-012026-06-3000010410242026-04-012026-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001041024us-gaap:CommonStockMember2026-04-012026-06-300001041024us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001041024us-gaap:PreferredStockMember2026-06-300001041024us-gaap:CommonStockMember2026-06-300001041024us-gaap:AdditionalPaidInCapitalMember2026-06-300001041024us-gaap:RetainedEarningsMember2026-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-3000010410242026-06-300001041024us-gaap:RetainedEarningsMember2026-07-012026-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-07-012026-09-300001041024us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001041024us-gaap:PreferredStockMember2026-09-300001041024us-gaap:CommonStockMember2026-09-300001041024us-gaap:AdditionalPaidInCapitalMember2026-09-300001041024us-gaap:RetainedEarningsMember2026-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-300001041024us-gaap:PreferredStockMember2024-12-310001041024us-gaap:CommonStockMember2024-12-310001041024us-gaap:AdditionalPaidInCapitalMember2024-12-310001041024us-gaap:RetainedEarningsMember2024-12-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-3100010410242024-12-310001041024us-gaap:RetainedEarningsMember2025-01-012025-03-3100010410242025-01-012025-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001041024us-gaap:CommonStockMember2025-01-012025-03-310001041024us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001041024us-gaap:PreferredStockMember2025-03-310001041024us-gaap:CommonStockMember2025-03-310001041024us-gaap:AdditionalPaidInCapitalMember2025-03-310001041024us-gaap:RetainedEarningsMember2025-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3100010410242025-03-310001041024us-gaap:RetainedEarningsMember2025-04-012025-06-3000010410242025-04-012025-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001041024us-gaap:CommonStockMember2025-04-012025-06-300001041024us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001041024us-gaap:PreferredStockMember2025-06-300001041024us-gaap:CommonStockMember2025-06-300001041024us-gaap:AdditionalPaidInCapitalMember2025-06-300001041024us-gaap:RetainedEarningsMember2025-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-3000010410242025-06-300001041024us-gaap:RetainedEarningsMember2025-07-012025-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001041024us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001041024us-gaap:CommonStockMember2025-07-012025-09-300001041024us-gaap:PreferredStockMember2025-09-300001041024us-gaap:CommonStockMember2025-09-300001041024us-gaap:AdditionalPaidInCapitalMember2025-09-300001041024us-gaap:RetainedEarningsMember2025-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-3000010410242025-09-300001041024rmti:CantorFitzgeraldCoMemberrmti:AtTheMarketOfferingMember2026-09-300001041024us-gaap:MediumTermNotesMemberrmti:TermLoanMember2024-01-022024-01-020001041024rmti:PendingAcquisitionMember2026-07-012026-09-300001041024rmti:PendingAcquisitionMember2026-01-012026-09-300001041024us-gaap:WarrantMember2026-07-012026-09-300001041024us-gaap:WarrantMember2025-07-012025-09-300001041024us-gaap:WarrantMember2026-01-012026-09-300001041024us-gaap:WarrantMember2025-01-012025-09-300001041024us-gaap:EmployeeStockOptionMember2026-07-012026-09-300001041024us-gaap:EmployeeStockOptionMember2025-07-012025-09-300001041024us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001041024us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001041024us-gaap:ConvertiblePreferredStockMember2026-07-012026-09-300001041024us-gaap:ConvertiblePreferredStockMember2025-07-012025-09-300001041024us-gaap:ConvertiblePreferredStockMember2026-01-012026-09-300001041024us-gaap:ConvertiblePreferredStockMember2025-01-012025-09-300001041024us-gaap:RestrictedStockUnitsRSUMember2026-07-012026-09-300001041024us-gaap:RestrictedStockUnitsRSUMember2025-07-012025-09-300001041024us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300001041024us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300001041024rmti:RestrictedStockUnitsMarketConditionMember2026-07-012026-09-300001041024rmti:RestrictedStockUnitsMarketConditionMember2025-07-012025-09-300001041024rmti:RestrictedStockUnitsMarketConditionMember2026-01-012026-09-300001041024rmti:RestrictedStockUnitsMarketConditionMember2025-01-012025-09-300001041024us-gaap:RestrictedStockMember2026-07-012026-09-300001041024us-gaap:RestrictedStockMember2025-07-012025-09-300001041024us-gaap:RestrictedStockMember2026-01-012026-09-300001041024us-gaap:RestrictedStockMember2025-01-012025-09-3000010410242026-07-012026-07-010001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerAMemberus-gaap:SalesRevenueNetMember2026-07-012026-09-300001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerAMemberus-gaap:SalesRevenueNetMember2026-01-012026-09-300001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerAMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerAMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-300001041024rmti:CustomerAMember2026-07-012026-09-300001041024rmti:CustomerAMember2026-01-012026-09-300001041024rmti:CustomerAMember2025-07-012025-09-300001041024rmti:CustomerAMember2025-01-012025-09-300001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerBMemberus-gaap:SalesRevenueNetMember2026-07-012026-09-300001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerCMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerCMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-300001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerBMemberus-gaap:AccountsReceivableMember2026-07-012026-09-300001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerCMemberus-gaap:AccountsReceivableMember2026-01-012026-09-300001041024rmti:CustomerAMember2026-09-300001041024rmti:CustomerAMember2025-12-310001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerAMemberus-gaap:AccountsReceivableMember2026-01-012026-09-300001041024us-gaap:CustomerConcentrationRiskMemberrmti:CustomerAMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001041024rmti:DistributionAndLicensingAgreementsMember2026-01-012026-09-300001041024rmti:ProductsPurchaseAgreementMember2026-01-012026-03-310001041024rmti:ProductsPurchaseAgreementMember2025-07-012025-09-300001041024rmti:ProductsPurchaseAgreementMember2025-01-012025-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductsMember2026-07-012026-09-300001041024us-gaap:TransferredAtPointInTimeMembercountry:USrmti:ConcentrateProductsMember2026-07-012026-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:ConcentrateProductsMember2026-07-012026-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductsMember2026-01-012026-09-300001041024us-gaap:TransferredAtPointInTimeMembercountry:USrmti:ConcentrateProductsMember2026-01-012026-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:ConcentrateProductsMember2026-01-012026-09-300001041024country:US2026-07-012026-09-300001041024us-gaap:NonUsMember2026-07-012026-09-300001041024country:US2026-01-012026-09-300001041024us-gaap:NonUsMember2026-01-012026-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2025-07-012025-09-300001041024us-gaap:TransferredOverTimeMemberus-gaap:NonUsMemberrmti:ConcentrateProductLicenseFeeMember2025-07-012025-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2025-01-012025-09-300001041024us-gaap:TransferredOverTimeMembercountry:USrmti:ConcentrateProductLicenseFeeMember2025-01-012025-09-300001041024us-gaap:TransferredOverTimeMemberus-gaap:NonUsMemberrmti:ConcentrateProductLicenseFeeMember2025-01-012025-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductsMember2025-07-012025-09-300001041024us-gaap:TransferredAtPointInTimeMembercountry:USrmti:ConcentrateProductsMember2025-07-012025-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:ConcentrateProductsMember2025-07-012025-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductsMember2025-01-012025-09-300001041024us-gaap:TransferredAtPointInTimeMembercountry:USrmti:ConcentrateProductsMember2025-01-012025-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:ConcentrateProductsMember2025-01-012025-09-300001041024country:US2025-07-012025-09-300001041024us-gaap:NonUsMember2025-07-012025-09-300001041024country:US2025-01-012025-09-300001041024us-gaap:NonUsMember2025-01-012025-09-3000010410242024-01-010001041024rmti:ConcentrateProductsMember2026-09-300001041024rmti:ConcentrateProductsMember2025-12-310001041024us-gaap:CustomerRelationshipsMember2026-09-300001041024us-gaap:CustomerRelationshipsMember2025-12-310001041024us-gaap:CustomerRelationshipsMember2025-07-012025-09-300001041024us-gaap:CustomerRelationshipsMember2026-07-012026-09-300001041024us-gaap:CustomerRelationshipsMember2025-01-012025-09-300001041024us-gaap:CustomerRelationshipsMember2026-01-012026-09-300001041024rmti:ReportableSegmentMember2026-07-012026-09-300001041024rmti:ReportableSegmentMember2025-07-012025-09-300001041024rmti:ReportableSegmentMember2026-01-012026-09-300001041024rmti:ReportableSegmentMember2025-01-012025-09-300001041024us-gaap:MachineryAndEquipmentMember2026-09-300001041024us-gaap:MachineryAndEquipmentMember2025-12-310001041024us-gaap:OfficeEquipmentMember2026-09-300001041024us-gaap:OfficeEquipmentMember2025-12-310001041024us-gaap:LeaseholdImprovementsMember2026-09-300001041024us-gaap:LeaseholdImprovementsMember2025-12-310001041024us-gaap:OtherMachineryAndEquipmentMember2026-09-300001041024us-gaap:OtherMachineryAndEquipmentMember2025-12-310001041024rmti:DaVitaHealthcarePartnersIncMemberrmti:SeriesXConvertiblePreferredStockMemberus-gaap:PrivatePlacementMember2022-04-060001041024rmti:SeriesXConvertiblePreferredStockMember2022-04-062022-04-060001041024rmti:SeriesXConvertiblePreferredStockMember2022-04-060001041024us-gaap:RestrictedStockMember2026-09-300001041024us-gaap:RestrictedStockMember2025-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2026-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2025-09-300001041024rmti:RestrictedStockUnitsMarketConditionMember2026-09-300001041024rmti:RestrictedStockUnitsMarketConditionMember2025-09-300001041024rmti:PrivatePlacementWarrantsMember2026-09-300001041024rmti:PrivatePlacementWarrantsMember2025-09-300001041024rmti:CantorFitzgeraldCoMemberrmti:AtTheMarketOfferingMember2024-11-130001041024rmti:AtTheMarketOfferingMemberus-gaap:CommonStockMember2026-07-012026-09-300001041024rmti:AtTheMarketOfferingMemberus-gaap:CommonStockMember2026-01-012026-09-300001041024us-gaap:MediumTermNotesMemberrmti:TermLoanMember2024-01-020001041024rmti:ArmisticeReloadWarrantAgreementMember2023-07-100001041024rmti:ArmisticeReloadWarrantAgreementMember2023-07-102023-07-1000010410242023-07-1000010410242026-07-0100010410242022-05-092022-05-090001041024rmti:ServiceBasedRestrictedStockUnitsMember2026-07-012026-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2025-07-012025-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2026-01-012026-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2025-01-012025-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2026-07-012026-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2025-07-012025-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2026-01-012026-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2025-01-012025-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2025-12-310001041024rmti:PerformanceBasedRestrictedStockAwardsMember2026-01-012026-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2026-09-300001041024rmti:RestrictedStockUnitsMarketConditionMember2025-05-012025-05-310001041024rmti:RestrictedStockUnitsMarketConditionMember2026-07-012026-09-300001041024rmti:RestrictedStockUnitsMarketConditionMember2026-01-012026-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2025-12-310001041024rmti:ServiceBasedRestrictedStockUnitsMembersrt:MinimumMember2026-01-012026-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMembersrt:MaximumMember2026-01-012026-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2026-09-300001041024rmti:ServiceBasedStockOptionAwardsMembersrt:MinimumMember2025-09-300001041024rmti:ServiceBasedStockOptionAwardsMembersrt:MaximumMember2025-09-300001041024rmti:ServiceBasedStockOptionAwardsMembersrt:MinimumMember2025-01-012025-09-300001041024rmti:ServiceBasedStockOptionAwardsMembersrt:MaximumMember2025-01-012025-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2025-12-3100010410242018-10-072018-10-070001041024rmti:MasterServicesAndIpAgreementMember2026-09-300001041024rmti:MasterServicesAndIpAgreementMember2025-12-310001041024srt:MaximumMember2026-09-300001041024stpr:MIrmti:WixomMichiganPropertyOneMember2026-09-300001041024stpr:MIrmti:WixomMichiganPropertyTwoMember2026-09-300001041024stpr:TX2026-09-300001041024stpr:TX2026-01-3100010410242026-01-310001041024stpr:PA2026-09-300001041024us-gaap:OperatingLeaseLeaseNotYetCommencedMemberrmti:NewtownSquareMember2026-09-300001041024us-gaap:OperatingLeaseLeaseNotYetCommencedMemberrmti:NewtownSquareMember2026-01-012026-09-300001041024rmti:NewtownSquareMember2026-09-300001041024us-gaap:MediumTermNotesMemberrmti:TermLoanMember2020-03-162020-03-160001041024us-gaap:MediumTermNotesMemberrmti:TermLoanTrancheOneMember2020-03-160001041024us-gaap:MediumTermNotesMemberrmti:TermLoanMembersrt:MaximumMember2024-01-022024-01-020001041024us-gaap:MediumTermNotesMemberrmti:TermLoanMember2026-09-300001041024us-gaap:MediumTermNotesMemberrmti:TermLoanMember2025-12-310001041024us-gaap:MediumTermNotesMember2026-09-300001041024us-gaap:NotesPayableToBanksMemberrmti:A7.89NotePayableMember2025-06-030001041024us-gaap:NotesPayableToBanksMemberrmti:A7.89NotePayableMember2025-06-032025-06-030001041024us-gaap:NotesPayableToBanksMemberrmti:A7.89NotePayableMember2024-06-040001041024us-gaap:NotesPayableToBanksMemberrmti:A7.89NotePayableMember2024-06-042024-06-040001041024us-gaap:SubsequentEventMemberrmti:VantiveLimitedMember2026-11-022026-11-020001041024us-gaap:SubsequentEventMemberrmti:VantiveLimitedMemberrmti:TermLoanMember2026-11-020001041024us-gaap:SubsequentEventMemberrmti:VantiveLimitedMemberus-gaap:ConvertibleNotesPayableMember2026-11-020001041024us-gaap:SubsequentEventMemberrmti:VantiveLimitedMember2026-11-020001041024us-gaap:SubsequentEventMemberrmti:EBITDABasedPaymentsOverEightYearsMemberrmti:VantiveLimitedMember2026-11-020001041024us-gaap:SubsequentEventMemberrmti:EBITDABasedPaymentsOverEightYearsMemberrmti:VantiveLimitedMember2026-11-022026-11-020001041024us-gaap:SubsequentEventMemberrmti:RevenueBasedPaymentsOverFiveYearsMemberrmti:VantiveLimitedMember2026-11-022026-11-020001041024us-gaap:SubsequentEventMemberrmti:RevenueBasedPaymentsOverFiveYearsMemberrmti:VantiveLimitedMember2026-11-020001041024us-gaap:SubsequentEventMemberrmti:VantiveLimitedMemberus-gaap:ConvertibleNotesPayableMember2026-11-022026-11-020001041024us-gaap:SubsequentEventMemberrmti:VantiveLimitedMemberrmti:TermLoanMember2026-11-022026-11-020001041024us-gaap:SubsequentEventMemberrmti:VantiveLimitedMemberrmti:TwoTermLoansMember2026-11-020001041024us-gaap:SubsequentEventMemberrmti:VantiveLimitedMemberrmti:TermLoanMembersrt:MinimumMember2026-11-022026-11-020001041024us-gaap:SubsequentEventMemberrmti:VantiveLimitedMemberrmti:TermLoanMembersrt:MaximumMember2026-11-022026-11-02





United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
__________________________________________________
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2026
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                              to                              
Commission File Number: 000-23661
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware38-3317208
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
30142 S. Wixom Road, Wixom, Michigan
48393
(Address of principal executive offices)(Zip Code)
(248) 960-9009
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☒ Yes    ☐  No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  ☒  Yes    ☐  No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐  Yes ☒ No
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:Trading SymbolName of each exchange on which registered:
Common Stock, par value $0.0001RMTI
Nasdaq Capital Market
The number of shares of common stock outstanding as of November 9, 2026 was —.






Rockwell Medical, Inc. and Subsidiaries
Index to Form 10-Q
Page
Part I — Financial Information (unaudited)
Item 1 - Unaudited Financial Statements
Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025
3
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025
4
Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2026 and 2025
5
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025
6
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025
7
Notes to Condensed Consolidated Financial Statements
8
Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations
16
Item 3 - Quantitative and Qualitative Disclosures about Market Risk
20
Item 4 - Controls and Procedures
20
Part II — Other Information
Item 1 - Legal Proceedings
20
Item 1A - Risk Factors
20
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds
20
Item 3 - Defaults Upon Senior Securities
20
Item 4 - Mine Safety Disclosures
21
Item 5 - Other Information
21
Item 6 - Exhibits
21
Signatures
22
2





PART I – FINANCIAL INFORMATION
Item 1.  Financial Statements
ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and par value amounts)
September 30,
2026
December 31,
2025
ASSETS
Cash and Cash Equivalents$10,631 $10,711 
Investments Available-for-Sale11,910 14,286 
Accounts Receivable, net9,796 8,143 
Inventory, net2,935 3,424 
Prepaid and Other Current Assets1,901 1,599 
Total Current Assets37,173 38,163 
Property and Equipment, net4,906 4,629 
Right of Use Assets - Operating, net3,863 2,569 
Right of Use Assets - Finance, net346 651 
Intangible Assets, net9,242 9,656 
Goodwill921 921 
Other Non-Current Assets633 556 
Total Assets$57,084 $57,145 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable$3,644 $1,999 
Accrued Liabilities6,206 4,337 
Deferred Consideration - Current— 1,000 
Lease Liabilities - Operating - Current1,419 1,155 
Lease Liabilities - Finance - Current409 469 
Term Loans - Current - Net of Issuance Costs2,829 — 
Insurance Financing Note Payable— 264 
Customer Deposits566 356 
Total Current Liabilities15,073 9,580 
Lease Liabilities - Operating - Long-Term2,641 1,454 
Lease Liabilities - Finance - Long-Term14 304 
Term Loans - Long-Term, Net of Issuance Costs6,221 8,826 
Total Liabilities23,949 20,164 
Commitments and Contingencies (see Note 13)
Stockholders' Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 shares issued and outstanding at September 30, 2026 and December 31, 2025
— — 
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 3,971,968 and 3,940,530 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively
— — 
Additional Paid-in Capital441,115 439,842 
Accumulated Deficit(408,093)(402,992)
Accumulated Other Comprehensive Income113 131 
Total Stockholders’ Equity33,135 36,981 
Total Liabilities and Stockholders’ Equity$57,084 $57,145 
The accompanying notes are an integral part of the condensed consolidated financial statements.
3


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net Sales$19,122 $15,927 $54,238 $50,912 
Cost of Sales16,011 13,655 44,987 43,095 
Gross Profit3,111 2,272 9,251 7,817 
Research and Product Development114 — 154 — 
Selling and Marketing572 531 1,716 1,814 
General and Administrative3,799 3,325 11,296 10,296 
Transaction-related expenses847 — 847 — 
Operating Loss(2,221)(1,584)(4,762)(4,293)
Other Income (Expense):
Realized Gain on Available-for-Sale Investments128 61 378 181 
Interest Expense(282)(285)(845)(838)
Interest Income51 55 128 190 
Total Other Expense, net(103)(169)(339)(467)
Net Loss$(2,324)$(1,753)$(5,101)$(4,760)
Basic and Diluted Net Loss per Share$(0.59)$(0.49)$(1.33)$(1.41)
Basic and Diluted Weighted Average Shares Outstanding3,971,984 3,602,494 3,957,624 3,481,797 

The accompanying notes are an integral part of the condensed consolidated financial statements.
4


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands)
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net Loss$(2,324)$(1,753)$(5,101)$(4,760)
Reclassification of Realized Gain on Available-for-Sale Investments Included in Net Loss(128)(61)(378)(181)
Unrealized Gain on Available-for-Sale Investments111 77 360 200 
Comprehensive Loss$(2,341)$(1,737)$(5,119)$(4,741)

The accompanying notes are an integral part of the condensed consolidated financial statements.
5


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(In thousands, except share amounts)
PREFERRED STOCKCOMMON STOCKADDITIONAL PAID-IN CAPITALACCUMULATED
DEFICIT
ACCUMULATED
OTHER
COMPREHENSIVE
INCOME
TOTAL
STOCKHOLDERS'
 EQUITY
SHARESAMOUNTSHARESAMOUNT
Balance as of January 1, 2026
15,000 $— 3,940,530 $— $439,842 $(402,992)$131 $36,981 
Net Loss— — — — — (1,605)— (1,605)
Reclassification of Realized Gain on Available-for-Sale Investments— — — — — — (120)(120)
Unrealized Gain on Available-for-Sale Investments— — — — — — 122 122 
Vesting of Restricted Stock Units Issued, net of Taxes Withheld— — 6,499 — — — — — 
Stock-based Compensation— — — — 479 — — 479 
Balance as of March 31, 2026
15,000 $— 3,947,029 $— $440,321 $(404,597)$133 $35,857 
Net Loss— — — — — (1,172)— (1,172)
Reclassification of Realized Gain on Available-for-Sale Investments— — — — — — (130)(130)
Unrealized Gain on Available-for-Sale Investments— — — — — — 127 127 
Vesting of Restricted Stock Units Issued, net of Taxes Withheld— — 25,000 — — — — — 
Stock-based Compensation — — — — 403 — — 403 
Balance as of June 30, 2026
15,000 $— 3,972,029 $— $440,724 $(405,769)$130 $35,085 
Net Loss— — — — — (2,324)— (2,324)
Reclassification of Realized Gain on Available-for-Sale Investments— — — — — — (128)(128)
Unrealized Gain on Available-for-Sale Investments— — — — — — 111 111 
Cash Paid in Lieu of Fractional Shares in Reverse Stock Split— — (61)— — — — — 
Stock-based Compensation— — — — 391 — — 391 
Balance as of September 30, 2026
15,000 $— 3,971,968 $— $441,115 $(408,093)$113 $33,135 

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(In thousands, except share amounts)
PREFERRED STOCKCOMMON STOCKADDITIONAL PAID-IN CAPITALACCUMULATED
DEFICIT
ACCUMULATED
OTHER
COMPREHENSIVE INCOME
TOTAL
STOCKHOLDERS'
EQUITY
SHARESAMOUNTSHARESAMOUNT
Balance as of January 1, 2025
15,000 $— 3,405,692 $— $430,210 $(397,678)$54 $32,586 
Net Loss— — — — — (1,515)— (1,515)
Reclassification of Realized Gain on Available-for-Sale Investments— — — — — — (56)(56)
Unrealized Gain on Available-for-Sale Investments— — — — — — 62 62 
Vesting of Restricted Stock Units Issued, net of Taxes Withheld— — 20,098 — — — — — 
Stock-based Compensation— — — — 445 — — 445 
Balance as of March 31, 2025
15,000 $— 3,425,790 $— $430,655 $(399,193)$60 $31,522 
Net Loss— — — — — (1,492)— (1,492)
Reclassification of Realized Gains on Available-for-Sale Investments— — — — — — (64)(64)
Unrealized Gain on Available-for-Sale Investments— — — — — — 61 61 
Vesting of Restricted Stock Units Issued, net of Taxes Withheld— — 17,244 — — — — — 
Stock-based Compensation— — — — 382 — — 382 
Balance as of June 30, 2025
15,000 $— 3,443,034 $— $431,037 $(400,685)$57 $30,409 
Net Loss— — — — — (1,753)— (1,753)
Reclassification of Realized Gain on Available-for-Sale Investments— — — — — — (61)(61)
Unrealized Gain on Available-for-Sale Investments— — — — — — 77 77 
Issuance of Common Stock, net of offering costs/At-the-Market Offering— — 496,463 — 7,799 — — 7,799 
Issuance of Common Stock upon Exercise of Options— — 1,031 — 16 — — 16 
Stock-based Compensation— — — — 532 — — 532 
Balance as of September 30, 2025
15,000 $— 3,940,528 $— $439,384 $(402,438)$73 $37,019 

The accompanying notes are an integral part of the condensed consolidated financial statements.
6


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Nine Months Ended September 30,
20262025
Cash Flows From Operating Activities:
Net Loss$(5,101)$(4,760)
Adjustments To Reconcile Net Loss To Net Cash Provided By (Used In) Operating Activities:
Depreciation and Amortization1,553 1,646 
Stock-based Compensation1,273 1,359 
Write-off of Inventory— 178 
Change in Inventory Reserves— (61)
Change in Accounts Receivable Reserve for Chargebacks(315)— 
Non-cash Lease Expense from Right of Use Assets1,461 1,616 
Amortization of Debt Financing Costs and Accretion of Debt Discount and Premium225 265 
Loss on Disposal of Assets172 56 
Realized Gain on Sale of Investments(378)(181)
Gain on Early Termination of Lease Liability— (24)
Changes in Assets and Liabilities:
Accounts Receivable(1,338)(37)
Inventory489 1,875 
Prepaid and Other Assets(379)470 
Accounts Payable1,645 (1,344)
Operating Lease Liabilities(999)(1,229)
Accrued and Other Liabilities2,079 (2,304)
Deferred License Revenue— (475)
Net Cash Provided By (Used In) Operating Activities387 (2,950)
Cash Flows From Investing Activities:
Purchases of Investments Available-for-Sale(18,864)(12,957)
Proceeds from Sales of Investments Available-for-Sale21,600 9,000 
Purchases of Equipment(1,764)(456)
Proceeds from Sale of Equipment
175 — 
Net Cash Provided By (Used In) Investing Activities1,147 (4,413)
Cash Flows From Financing Activities:
Payments on Insurance Financing Note Payable(264)(466)
Payments on Finance Lease Liabilities(350)(418)
Proceeds from Issuance of Common Stock— 7,816 
Deferred Consideration Paid in Connection with Evoqua Asset Acquisition
(1,000)(1,621)
Net Cash (Used In) Provided By Financing Activities(1,614)5,311 
Net Decrease in Cash and Cash Equivalents(80)(2,052)
Cash and Cash Equivalents at Beginning of Period10,711 15,662 
Cash and Cash Equivalents at End of Period$10,631 $13,610 
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest$608 $575 
Supplemental Disclosure of Noncash Investing and Financing Activities:
Right of Use Assets - Operating Obtained in Exchange for Lease Liabilities - Operating$2,450 $1,006 
Change in Unrealized Gain on Investments Available-for-Sale$(18)$19 
Increase in Prepaid Assets from Insurance Financing Note Payable$— $660 
De-recognition of Lease Liability - Finance and ROU Asset - Finance upon early termination$— $228 
The accompanying notes are an integral part of the condensed consolidated financial statements.

7


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1.  Description of Business
Rockwell Medical, Inc. (the "Company", "Rockwell", or "Rockwell Medical") is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide.
Rockwell is a supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed in freestanding outpatient dialysis centers, at hospital-based outpatient centers, skilled nursing facilities, or a patient’s home.

Rockwell manufactures hemodialysis concentrates under current Good Manufacturing Practices ("cGMP") at its two facilities in Michigan and Texas, and manufactures dry acid concentrate mixers at its facility in Iowa. Rockwell delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally utilizing its own delivery trucks and third-party carriers.

Rockwell was incorporated in the state of Michigan in 1996 and re-domiciled to the state of Delaware in 2019. Our headquarters is located at 30142 S. Wixom Road, Wixom, Michigan 48393. Our telephone number is (248) 960-9009 and our website is https://www.rockwellmed.com.

2. Liquidity and Capital Resources
As of September 30, 2026, Rockwell had approximately $22.5 million of cash, cash equivalents and investments available-for-sale, and working capital of $22.1 million. Net cash provided by operating activities for the nine months ended September 30, 2026 was approximately $0.4 million. Based on the currently available working capital along with the expectation of management of its ability to execute on its operational plans as discussed below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.

The Company continues to review its operational plans and execute on the acquisition of new customers, and has implemented cost containment activities. The Company may require additional capital to sustain its operations and make the investments it needs to execute its strategic plan. In addition, the Company's plans may include raising capital, if needed, by using the $13.1 million remaining on its at-the-market ("ATM") facility or other methods or forms of financings. The proposed acquisition described in Note 17 may limit the Company’s ability to use the ATM facility or conduct other registered offerings until the required historical financial statements of the acquired business and related pro forma financial information have been filed. Accordingly, the remaining ATM capacity should not be viewed as committed or immediately available funding. See the discussion of these limitations in Part II, Item 1A, “Risk Factors.” In addition, any debt financing is limited by the terms of the Company's Securities Purchase Agreement with DaVita described in Note 11. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all. The Company will also need to fund transaction expenses, repayment of its existing debt and the working capital and integration requirements of the acquired business; the seller financing described in Note 17 principally funds the acquisition consideration.

The Company is subject to certain covenants and cure provisions under its Loan Agreement (as defined below in Note 15) with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), which, on January 2, 2024, was amended to include, among other things, an interest-only period for 36 months, and to extend the maturity date to January 1, 2029 (See Note 15 for further detail). The Company satisfied those conditions and will now make interest-only payments for the full 36 months. As of September 30, 2026, the Company is in compliance with all covenants.

The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, changes in U.S. trade policies, including tariffs and other trade restrictions or the threat of such actions, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the conflicts in the Middle East and other political tensions, and the occurrence of natural disasters and public health crises. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, the Company is unable to quantify the potential effects, if any, of this economic and political instability on its future operations.

Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly
evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.
3.  Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.

The condensed consolidated balance sheet at September 30, 2026, and the condensed consolidated statements of operations, comprehensive loss and changes in stockholders' equity for the three and nine months ended September 30, 2026 and 2025, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2026 and 2025 are unaudited, but include all adjustments, consisting of normal recurring adjustments the Company considers necessary for a fair presentation of the financial position, operating results, and cash flows for the periods presented. The results for the nine months ended September 30, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026 or for any future interim period. The condensed consolidated balance sheet at December 31, 2025 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2025 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 as filed with the SEC on March 26, 2026. The Company’s consolidated subsidiaries consist of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reverse Stock Split
On July 1, 2026, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock. All share and related per-share amounts for all periods presented in these condensed consolidated financial statements — including common shares outstanding, weighted-average shares outstanding, net loss per share, and the shares underlying stock options, restricted stock units, warrants, and the conversion of the Series X Convertible Preferred Stock — have been retrospectively adjusted to reflect the reverse stock split. See Note 11 for further information.

Vantive Transaction-Related Expenses
During the three and nine months ended September 30, 2026, the Company incurred $0.8 million of costs associated with a pending acquisition. These costs, consisting primarily of legal, consulting and other professional fees are presented as Transaction-related expenses within the accompanying Condensed Consolidated Statements of Operations.
Loss Per Share
Basic and diluted net loss per share for the three and nine months ended September 30, 2026 and 2025 was calculated as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands, except share and per share amounts)2026202520262025
Numerator:
Net Loss$(2,324)$(1,753)$(5,101)$(4,760)
Less: Accretion of Series X Preferred Stock— — (155)(153)
Net Loss Attributable to Common Stockholders$(2,324)$(1,753)$(5,256)$(4,913)
Denominator:
Weighted Average Number of Shares of Common Stock Outstanding - Basic and Diluted3,971,984 3,602,494 3,957,624 3,481,797 
Net Loss per Share Attributable to Common Stockholders - Basic and Diluted$(0.59)$(0.49)$(1.33)$(1.41)
Basic income (loss) per share (“EPS”) is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted EPS gives effect to the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock, using the more dilutive of the two- class method and the if-converted method in the period of earnings. The two-class method is an earnings allocation method that determines income (loss) per share (when there are earnings) for common stock and participating securities. The if-converted method assumes all convertible securities are converted into common stock. Potential shares of common stock are excluded from diluted EPS when their effect would be anti-dilutive.
The Company’s potentially dilutive securities include stock options, restricted stock awards and units, convertible preferred stock and warrants. The following table includes the potential shares of common stock that were excluded from the computation of diluted EPS attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Warrants to Purchase Common Stock398,447 398,447 398,447 398,447 
Options to Purchase Common Stock359,652 328,186 359,652 328,186 
Convertible Preferred Stock141,900 140,500 141,900 140,500 
Unvested Restricted Stock Units211,999 116,666 211,999 116,666 
Unvested Restricted Stock Units - Market Condition71,700 71,700 71,700 71,700 
Unvested Restricted Stock Awards— 89 — 89 
Total1,183,698 1,055,588 1,183,698 1,055,588 
Adoption of Recent Accounting Pronouncements and New Accounting Pronouncements
The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures there are sufficient controls in place to ascertain the Company’s consolidated financial statements properly reflect the change.
Recently Adopted Accounting Pronouncements
In July 2025, the Financial Accounting Standards Board ("FASB") issued the Accounting Standards Update ("ASU") 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which simplifies the estimation of credit losses on current accounts receivable and contract assets by allowing the election of a practical expedient to assume that the current conditions as of the consolidated balance sheet date will remain unchanged for the remaining life of the asset when developing a reasonable and supportable forecast as part of estimating expected credit losses on these assets. The Company adopted this ASU on January 1, 2026, and the adoption did not have a material impact on the Company’s consolidated financial statements or footnote disclosures.
New Accounting Pronouncements
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. This new standard is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently assessing the impact this ASU will have on the consolidated financial statements and footnote disclosures.
4.  Revenue Recognition

The Company recognizes revenue under Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers, issued by the FASB. The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:

•Step 1: Identify the contract with the customer
•Step 2: Identify the performance obligations in the contract
•Step 3: Determine the transaction price
•Step 4: Allocate the transaction price to the performance obligations in the contract
•Step 5: Recognize revenue when the company satisfies a performance obligation
Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by Rockwell from a customer, are excluded from revenue.
Certain distributors deduct distribution service fees from amounts due to the Company. These fees, along with chargebacks arising from contracted pricing arrangements with certain end customers, are recorded as reductions of revenue. Chargebacks represent the difference between the distributor’s acquisition cost and the lower contracted price offered to the end customer, and are estimated and recorded as a reduction of revenue at the time of the initial sale to the distributor. Chargeback estimates represent variable consideration and are determined based on contractual pricing arrangements, historical chargeback activity and expected sales to eligible end customers.
Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.
Nature of goods and services
Rockwell operates in one market segment, the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Rockwell's customer mix is diverse, with most customer sales concentrations under 10%. DaVita Inc. ("DaVita"), a related party (see Note 11), represented approximately 7% of total revenues for each of the three and nine months ended September 30, 2026, and 12% and 17% of total revenues for the three and nine months ended September 30, 2025, respectively. Revenue from DaVita was $1.4 million and $4.0 million for the three and nine months ended September 30, 2026 and $1.8
million and $8.7 million for the three and nine months ended September 30, 2025, respectively. Two other customers, Customer B and Customer C, each represented approximately 10% of total revenues for the three and nine months ended September 30, 2026, and Customer C represented 11% and 10% of total revenues for the three and nine months ended September 30, 2025, respectively. At September 30, 2026, Customer B and Customer C represented 14% and 22% of the total net consolidated accounts receivable balance, respectively. Accounts receivable due from DaVita were $0.7 million and $1.1 million at September 30, 2026 and December 31, 2025, respectively (7% and 14% of the consolidated net accounts receivable balance). See Product Purchase Agreement below.
Product Sales
The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.
Dialysis concentrate and ancillary products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales. For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales. In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer.
For the majority of the Company's international customers, the Company recognizes revenue when the customer takes control at the shipping point, which is generally the Company's plant or warehouse. For other customers, the Company recognizes revenue based on when the customer takes control of the product upon delivery. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers estimated at the time of sale. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while a small subset of customers have payment terms averaging 60 days.
Deferred License Revenue
The Company received upfront fees under three distribution and license agreements, which were recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India, South Korea and Turkey to determine that regulatory approval was probable as of the execution of the agreement. During the nine months ended September 30, 2025, all remaining deferred revenue relating to the distribution and license agreements was recognized, resulting in $0.3 million of revenue recorded. All license agreements have been terminated.
Product Purchase Agreement
On September 18, 2023, Rockwell and DaVita entered into an Amended and Restated Products Purchase Agreement (the "Amended Agreement"), which amends and restates the Product Purchase Agreement, dated July 1, 2019, as amended, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amended Agreement, the Company and DaVita agreed to an increase in product pricing, effective September 1, 2023. The term of the Amended Agreement was scheduled to expire on December 31, 2024. Prior to the expiration, the Company received written notice from DaVita, notifying the Company that DaVita intended to extend the term of the Amended Agreement through December 31, 2025 (the "Extension Term"). However, DaVita subsequently indicated that it would completely transition to another supplier, subject to further discussion between Rockwell and DaVita. DaVita agreed to non-refundable payments to ensure supply continuity during the transition period for products purchased, including quarterly, non-refundable payments totaling $2.0 million during the year ended December 31, 2025, of which $0.4 million and $1.7 million were recorded as revenue during the three and nine months ended September 30, 2025. On December 23, 2025, DaVita and the Company extended the term of the Amended Agreement through December 31, 2026 (as amended, the " Second Extension Term") with an increase in product pricing during the Second Extension Term.
Disaggregation of revenue
Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
In thousandsThree Months Ended September 30, 2026Nine Months Ended September 30, 2026
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Concentrate Product Sales - Point-in-Time$19,122 $16,231 $2,891 $54,238 $45,925 $8,313 
Net Revenue$19,122 $16,231 $2,891 $54,238 $45,925 $8,313 

In thousandsThree Months Ended September 30, 2025Nine Months Ended September 30, 2025
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
License Fee – Over Time$— $— $— $325 $— $325 
Concentrate Product Sales - Point-in-Time15,927 13,824 2,103 50,587 44,449 6,138 
Net Revenue$15,927 $13,824 $2,103 $50,912 $44,449 $6,463 
Contract balances
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.
In thousandsSeptember 30, 2026December 31, 2025January 1, 2025
Accounts Receivable, net$9,796 $8,143 $8,291 
Contract Liabilities, which were included in Deferred License Revenue$— $— $475 
There were no other material contract assets recorded on the condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025. The Company does not generally accept returns of its concentrate products and no material provision for returns of concentrates products was established as of September 30, 2026 or December 31, 2025. As of September 30, 2026 and December 31, 2025, the Company recorded an accrual for chargebacks and distribution fees of $0.7 million and $1.1 million, respectively, which are presented as an offset to accounts receivable in the accompanying condensed consolidated balance sheets.
5.  Intangible Assets and Deferred Consideration
Intangible Assets
Our customer relationship intangible asset relates to customer relationships acquired in connection with an acquisition (the "Evoqua Asset Acquisition") executed on July 10, 2023 with Evoqua Water Technologies LLC ("Evoqua").
The details of our intangible assets subject to amortization are set forth below (in thousands):
September 30, 2026
Useful LifeGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Customer Relationships20 years$11,035 $(1,793)$9,242 
December 31, 2025
Useful LifeGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Customer Relationships20 years$11,035 $(1,379)$9,656 
8


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
During each of the three months ended September 30, 2026 and 2025, the Company recorded amortization of its customer relationship intangible asset of $0.1 million. During each of the nine months ended September 30, 2026 and 2025, the Company recorded amortization of its customer relationship intangible asset of $0.4 million.
Estimated future amortization expense on the Company's customer relationships intangible asset as of September 30, 2026 is as follows (table in thousands):
Year ending December 31:
2026 (Remainder of Year)$138 
2027552 
2028552 
2029552 
2030552 
Thereafter6,896 
Total$9,242 
Deferred Consideration
A portion of the purchase price of the Evoqua Asset Acquisition was deferred on the acquisition date and was reflected in Deferred Consideration on the condensed consolidated balance sheet. The Company made payments of $1.0 million during the nine months ended September 30, 2026, which satisfied the remaining deferred consideration liability. The Company made payments of $1.6 million, during the nine months ended September 30, 2025.
6.  Investments - Available-for-Sale
Investments available-for-sale consisted of the following as of September 30, 2026 and December 31, 2025 (table in thousands):
September 30, 2026
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Debt Securities$11,791 $119 $— $— $11,910 

December 31, 2025
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Debt Securities$14,149 $137 $— $— $14,286 
The fair value of investments available-for-sale is determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and is classified as a Level 1 measurement under ASC 820, Fair Value Measurements.
During the three and nine months ended September 30, 2026, the Company sold investments outstanding for a gain of $0.1 million and $0.4 million, respectively. During the three and nine months ended September 30, 2025, the Company sold investments outstanding for a gain of $0.1 million and $0.2 million, respectively. These gains are included in realized gain on available-for-sale investments on the condensed consolidated statements of operations.
As of September 30, 2026, the Company's remaining available-for-sale securities are U.S. Department of the Treasury bonds and are all due within one year.
7. Segment Reporting

9


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Operating segments are defined as components of an entity about which discrete financial information is evaluated regularly by the Company's Chief Operating Decision Maker ("CODM") in deciding how to allocate resources and assess performance. Rockwell operates in one market segment, the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including dialysis concentrates and other ancillary products used in the dialysis process. Accordingly, the Company has one reportable segment. The Company has a single management team that reports to its Chief Executive Officer, the Company's CODM, who comprehensively manages the entire Company. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.

The CODM assesses performance for the segment and decides how to allocate resources based on net loss that also is reported on the statements of operations and comprehensive loss as net loss. The CODM uses net loss to monitor budget and forecast versus actual results in assessing segment performance, as well as cash forecast models, in order to evaluate operating results and performance in deciding how to allocate resources. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.

The Company’s significant segment expenses for its one segment for the three and nine months ended September 30, 2026 and 2025 consisted of the following (table in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net Sales$19,122 $15,927 $54,238 $50,912 
Cost of Sales16,011 13,655 44,987 43,095 
Gross Profit3,111 2,272 9,251 7,817 
Employee Compensation2,665 2,539 7,875 7,598 
Administrative Costs1,820 1,317 5,291 4,512 
Transaction-related expenses847 — 847 — 
Operating Loss(2,221)(1,584)(4,762)(4,293)
Other Income (Expense):
Realized Gain on Available-for-Sale Investments128 61 378 181 
Interest Expense(282)(285)(845)(838)
Interest Income51 55 128 190 
Total Other Expense, net(103)(169)(339)(467)
Net Loss$(2,324)$(1,753)$(5,101)$(4,760)
8.  Inventory
Components of inventory, net of reserves, as of September 30, 2026 and December 31, 2025 were as follows (table in thousands):
September 30,
2026
December 31,
2025
Inventory - Current Portion
Raw Materials$1,889 $1,848 
Work in Process216 199 
Finished Goods830 1,377 
Total Inventory$2,935 $3,424 
As of September 30, 2026 and December 31, 2025, Rockwell had total current concentrate inventory aggregating $2.9 million and $3.4 million, respectively, against which Rockwell had reserved $25.0 thousand at each period end.
10


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
9.  Property and Equipment
As of September 30, 2026 and December 31, 2025, the Company’s property and equipment consisted of the following (table in thousands):
September 30,
2026
December 31,
2025
Machinery and Equipment$10,544 $11,340 
Information Technology & Office Equipment1,070 1,717 
Leasehold Improvements1,359 1,567 
Laboratory Equipment298 726 
Total Property and Equipment13,271 15,350 
Accumulated Depreciation(8,365)(10,721)
Property and Equipment, net$4,906 $4,629 

During the nine months ended September 30, 2026, the Company disposed of certain property and equipment, resulting in the derecognition of $3.8 million of gross assets and $3.5 million of accumulated depreciation, proceeds of $0.2 million from asset sales, and a net loss on disposal of $0.2 million. Depreciation and amortization expense was $0.4 million for both of the three months ended September 30, 2026 and 2025. Depreciation and amortization expense for the nine months ended September 30, 2026 and 2025 was $1.1 million and $1.2 million, respectively.
10.  Accrued Liabilities
Accrued liabilities as of September 30, 2026 and December 31, 2025 consisted of the following (table in thousands):
September 30,
2026
December 31,
2025
Accrued Compensation and Benefits$1,833 $2,558 
Accrued Unvouchered Receipts1,612 814 
Accrued Workers Compensation79 84 
Accrued Legal Expense934 46 
Other Accrued Liabilities1,748 835 
Total Accrued Liabilities$6,206 $4,337 
11.  Stockholders’ Equity
Preferred Stock
On April 6, 2022, the Company and DaVita entered into the Securities Purchase Agreement (the "SPA"), which provided for the issuance by the Company of up to $15 million of preferred stock to DaVita, which was issued to DaVita during 2022 as Series X Preferred Stock and, by virtue thereof, made DaVita a related party.

The Series X Preferred Stock was issued for a price of $1,000 per share (the "Face Amount"), subject to accretion at a rate of 1% per annum, compounded annually. If the Company’s common stock trades above $220.00 for a period of 30 calendar days, the accretion will thereafter cease. As of September 30, 2026, a total of $0.6 million of the Series X Preferred Stock had been accreted, of which $0.2 million was accreted during each of the nine months ended September 30, 2026 and 2025. No accretion was recorded during the three months ended September 30, 2026 and 2025.

The Series X Convertible Preferred Stock is convertible to common stock at a rate equal to the Face Amount, divided by a conversion price of $110.00 per share (subject to adjustment for future stock splits, reverse stock splits and similar recapitalization events). As a result, each share of Series X Preferred Stock will initially convert into approximately 9 shares of common stock. DaVita’s right to convert to common stock is subject to a beneficial ownership limitation, which is initially set at 9.9% of the outstanding common stock, which limitation may be reset (not to exceed 19.9%) at DaVita’s option and upon
providing prior written notice to the Company. In addition, any debt financing is limited by the terms of our SPA with DaVita. Specifically, until DaVita holds less than 50% of its original investment in the Company's Series X Convertible Preferred Stock, the Company may only incur additional debt in the form of a purchase money loan, a working capital line of up to $5 million or to refinance existing debt, unless DaVita consents.

Additionally, the Series X Preferred Stock has a deemed liquidation event and redemption clause which could be triggered upon the sale of all or substantially all of the Company's assets relating to the Company's dialysis concentrates business line. Since the Series X Preferred Stock may be redeemed if certain assets are sold at the option of the holder, but is not mandatorily redeemable as the sale of the assets that would allow for redemption is within the control of the Company, the preferred stock has been classified as permanent equity and initially recognized at fair value of $15 million (the proceeds on the date of issuance) less issuance costs of $0.1 million, resulting in an initial value of $14.9 million. The Company will assess at each reporting period whether conditions have changed to now meet the mandatory redemption definition which could trigger liability classification.

As of each of September 30, 2026 and December 31, 2025, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and 15,000 shares of preferred stock issued and outstanding.
Common Stock
As of September 30, 2026 and 2025, the Company reserved for issuance the following shares of common stock related to the potential exercise of employee stock options, unvested restricted stock, convertible preferred stock, and warrants (collectively, "common stock equivalents"):
As of September 30,
Common Stock and Common Stock Equivalents:20262025
Common Stock3,971,968 3,940,528 
Options to Purchase Common Stock359,652 328,186 
Unvested Restricted Stock Awards— 89 
Unvested Restricted Stock Units211,999 116,666 
Convertible Preferred Stock141,900 140,500 
Unvested Restricted Stock Units - Market Condition71,700 71,700 
Warrants to Purchase Common Stock398,447 398,447 
Total5,155,666 4,996,116 
Controlled Equity Offering
On April 8, 2022, the Company entered into a Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. (the "Agent"), pursuant to which the Company may offer and sell from time to time shares of Company’s common stock through the Agent pursuant to the Company’s shelf registration statement on Form S-3 (No. 333-259923) filed with the SEC on September 30, 2021 (the “Prior Registration Statement”).
This Prior Registration Statement expired on October 8, 2024 and, upon the effectiveness of the Company's registration statement on October 21, 2024, was deemed terminated. On November 13, 2024, in connection with the new registration statement, the Company filed a prospectus supplement covering the offer and sale of an aggregate offering price of up to $25.0 million of shares of the Company's common stock through the Agent under the Sales Agreement (as amended, the "ATM facility"). The offering and sale of such shares has been registered under the Securities Act of 1933, as amended.
During the three and nine months ended September 30, 2026, no shares were sold pursuant to the Sales Agreement. Approximately $13.1 million remains available for sale under the ATM facility.

Warrant Issuance
In connection with the execution of the Third Amendment, as defined and described in Note 15, on January 2, 2024, the Company issued to Innovatus a warrant to purchase 19,109 shares of the Company’s common stock with an exercise price of $18.30 per share. The warrant may be exercised on a cashless basis, and is immediately exercisable through January 2, 2029. The number of shares of common stock for which the warrant is exercisable and the exercise price are subject to certain proportional adjustments as set forth in the Third Amendment. The warrant is equity-classified with a fair value of approximately $0.2 million at issuance, which was treated as a debt issuance cost and is being amortized through interest expense over the remaining contractual term of the Term Loans, as defined and described in Note 15.
On July 10, 2023, the Company entered into a letter agreement (the “Letter Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice”), in which Armistice would receive a “reload” warrant (the “Reload Warrant”) to purchase 375,000 shares of Common Stock with an exercise price of $51.30 per share, the closing price as reported by the Nasdaq Capital Market on July 7, 2023. The Reload Warrant may be exercised at all times prior to the 54 months anniversary of its issuance date. The Reload Warrant provides that a holder (together with its affiliates) may not exercise any portion of the Reload Warrant to the extent that the holder would own more than 9.99% of the Company’s outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of such warrant.
Reverse Stock Split
On July 1, 2026, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock. The reverse stock split was approved by the Company's stockholders at the annual meeting held on June 12, 2026. At the effective time, every ten shares of the Company's issued and outstanding common stock were combined into one issued and outstanding share of common stock. Immediately prior to the effective time there were 39,720,299 shares of common stock issued and outstanding, and immediately following the effective time there were 3,971,968 shares of common stock issued and outstanding, after giving effect to the cash paid in lieu of fractional shares. The par value of the common stock remained $0.0001 per share, and the number of authorized shares of common stock remained 170,000,000.
No fractional shares were issued in connection with the reverse stock split. In lieu of any fractional share, each stockholder who would otherwise have been entitled to a fractional share received a cash payment (without interest) equal to the fraction of a share to which the stockholder would otherwise have been entitled multiplied by the closing price of the common stock on June 30, 2026, as adjusted for the reverse stock split ratio. Cash paid in lieu of fractional shares was not material.
In accordance with the terms of the respective instruments, proportionate adjustments were made to (i) the number of shares subject to, and the exercise or grant prices of, outstanding equity awards and the shares reserved for issuance under the Company's equity incentive plans, (ii) the conversion price of, and the number of shares of common stock issuable upon conversion of, the Company's Series X Convertible Preferred Stock and (iii) the exercise prices of, and the number of shares of common stock issuable upon exercise of, the Company's outstanding warrants. The reduction in issued and outstanding shares resulting from the reverse stock split was recorded as a reclassification between common stock and additional paid-in-capital, which was not material, with no change to stockholders' equity.
The common stock began trading on a split-adjusted basis on the Nasdaq Capital Market at the open of trading on July 1, 2026, under the existing symbol “RMTI” and a new CUSIP number (774374409). The Company effected the reverse stock split to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). On May 8, 2026, the Company received notice from Nasdaq that it did not meet the minimum bid price requirement and was provided a compliance period through November 4, 2026. On July 16, 2026, the Company received notice from Nasdaq that it had regained compliance with the minimum bid price requirement, and Nasdaq closed the matter.
11


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
12.  Stock-Based Compensation
The Company recognized total stock-based compensation expense during the three and nine months ended September 30, 2026 and 2025 as follows (table in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Service-based Awards:
Restricted Stock Units$213 $263 $553 $744 
Stock Option Awards178 269 720 615 
Total$391 $532 $1,273 $1,359 
Performance-based Restricted Stock Awards
A summary of the Company’s performance-based restricted stock awards during the nine months ended September 30, 2026 is as follows:
Performance-based Restricted Stock AwardsNumber of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202689 $627.00 
Forfeited(89)$627.00 
Unvested at September 30, 2026— $— 
Performance-based restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of September 30, 2026, there is no unrecognized stock-based compensation expense related to performance-based restricted stock awards.
Restricted Stock Units - Market Condition
In May 2025, the Company granted 71,700 restricted stock units with a market condition ("RSU-MC") under its Amended and Restated 2018 Long Term Incentive Plan with a grant date fair value of $0.6 million. The RSU-MCs are subject to both service and market based vesting conditions.
The RSU-MCs will vest, subject to the recipient's continued employment through the vesting date, if the average closing price of the Company's common stock equals or exceeds $21.40 per share for any consecutive 60-day trading period occurring prior to the third anniversary of the grant date. Except in the event of a change in control or termination due to death or disability, no portion of the award will vest before the first anniversary of the grant date. The RSU-MCs qualify as equity instruments and are accounted for under ASC 718, Compensation, Stock Compensation.

The unrecognized stock-based compensation expense recorded in connection with the RSU-MCs was $0.3 million at September 30, 2026, which is expected to be recognized over the next 1.64 years.
Service-based Restricted Stock Units
A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2026 is as follows:
12


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Service-based Restricted Stock UnitsNumber of SharesWeighted Average
Grant-Date Fair Value
Unvested at January 1, 2026115,666 $11.10 
Granted138,165 5.19 
Vested(38,332)11.40 
Forfeited(3,500)10.70 
Unvested at September 30, 2026211,999 $7.21 
The fair value of service-based restricted stock units is measured on the date of grant and amortized over the vesting period. The vesting periods range from one to three years. As of September 30, 2026, the unrecognized stock-based compensation expense was $0.8 million, which is expected to be recognized over the next 1.68 years.
Service-based Stock Option Awards
The fair value of the service-based stock option awards granted during the nine months ended September 30, 2026 and 2025 were based on the following assumptions:
Nine Months Ended September 30, 2026Nine Months Ended September 30, 2025
Exercise price$5.19
$10.70 - $12.60
Expected stock price volatility90.9%
90.4% - 91.2%
Risk-free interest rate4.28%
3.74% - 4.14%
Term (years)5.86
5.62 - 5.86
A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2026 is as follows:
Service-based Stock Option AwardsShares
Underlying
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic Value
(in thousands)
Outstanding at January 1, 2026327,627 $26.40 — 
Granted47,250 5.19 
Forfeited(9,851)11.61 
Expired(5,374)70.23 
Outstanding at September 30, 2026
359,652 $23.20 7.57$— 
Exercisable at September 30, 2026
201,953 $32.70 6.67$— 
The aggregate intrinsic value is calculated as the difference between the closing price of the Company's common stock at the date indicated and the exercise price of the stock options that had strike prices below the closing price.
As of September 30, 2026, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $0.5 million, which is expected to be recognized over the next 1.98 years.
13.  Commitments and Contingencies
From time to time, the Company has been or may become a party to various disputes, legal actions, proceedings and investigations involving claims incidental to the conduct of its business, including actions by customers, employees, government entities and third parties. Due to the contract-intensive nature of the Company's business, the Company has been or may in the
13


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
future become involved in disputes or legal actions with its contract counterparties, which could have a negative impact on the Company's business, results of operations or financial condition.
Product License Agreements
The Company is a party to a Licensing Agreement between the Company and Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to its Triferic product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the Charak MSA, the parties entered into three additional agreements related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. These agreements granted the Company an exclusive, worldwide, non-transferable license to SFP for the purpose of commercializing (i) SFP for the treatment of patients with renal failure, (ii) certain intravenous-delivered products incorporating SFP for the treatment of iron disorders, and (iii) certain TPN products incorporating SFP. The potential milestone payments are not considered probable, and no milestone payments have been accrued as of September 30, 2026 and December 31, 2025.
14.  Leases
Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to six years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2027. Rockwell also occupies a 51,000 square foot facility in Grapevine, Texas. The lease, which previously expired in December 2025, was extended in January 2026 for a 62-month term through February 2031, resulting in the recognition of a right-of-use asset and corresponding lease liability of approximately $2.5 million. Additionally, Rockwell leases 16,800 square foot storage facility in Allentown, Pennsylvania, that expires in April 2030. The Company entered into a lease for approximately 8,700 square feet of office space in Newtown Square, Pennsylvania, for a term of five years commencing October 1, 2026, with total fixed lease payments of approximately $1.6 million. Because the lease commenced after September 30, 2026, no right-of-use asset or lease liability for this lease is recorded in the condensed consolidated balance sheet as of September 30, 2026 or reflected in the maturity table below.
The following summarizes quantitative information about the Company’s operating and finance leases (table in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Operating Leases
Operating Lease Cost$471 $477 $1,471 $1,391 
Variable Lease Cost100 146 267 411 
Operating Lease Expense571 623 1,738 1,802 
Finance Leases
Amortization of Right-of-Use Assets102 109 305 387 
Interest on Lease Obligations7 16 29 59 
Finance Lease Expense109 125 334 446 
Short-term Lease Rent Expense1 5 12 16 
Total Lease Expense$681 $753 $2,084 $2,264 
Other Information
Operating Cash Flows from Operating Leases$423 $483 $1,314 $1,385 
Operating Cash Flows from Finance Leases$7 $46 $29 $89 
Financing Cash Flows from Finance Leases$118 $124 $350 $418 
September 30,
20262025
Weighted-average Remaining Lease Term – Operating Leases3.52.7
Weighted-average Remaining Lease Term – Finance Leases0.91.9
Weighted-average Discount Rate – Operating Leases10.0 %7.9 %
Weighted-average Discount Rate – Finance Leases6.9 %6.8 %
Future minimum rental payments under operating and finance lease agreements are as follows (table in thousands):
OperatingFinance
Year ending December 31, 2026 (Remaining)$459 $125 
Year ending December 31, 20271,556 311 
Year ending December 31, 2028987 — 
Year ending December 31, 2029953 — 
Year ending December 31, 2030794 — 
Thereafter117 — 
Total4,866 436 
Less Present Value Discount(806)(13)
Operating and Finance Lease Liabilities$4,060 $423 
15. Loan and Security Agreement

On March 16, 2020, the Company and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus, as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company (the "Term Loans"). In connection with each funding of the Term Loans, the Company issued to Innovatus a warrant (each a “Warrant”, and together the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loans funded divided by the exercise price. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 4,338 shares of the Company’s common stock at an exercise price of $181.50 per share. The Warrant may be exercised on a cashless basis and is immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which the Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the Warrant using the Black-Scholes model.
On January 2, 2024, the Company entered into the Third Amendment to and Restatement of the Loan and Security Agreement (the "Third Amendment") with Innovatus, dated January 1, 2024 (the "Effective Date"). The Third Amendment provides for the continuation of term loans initially borrowed under the Loan Agreement amounting to $8.0 million as of January 1, 2024. The Company will make interest-only payments on the Term Loans for 36 months as certain conditions in the Third Amendment were met. The Company will make equal monthly payments of principal, together with applicable interest, in arrears, starting February 1, 2027. The Term Loans will mature on January 1, 2029. Effective on January 1, 2024, the Term Loans bear interest equal to the sum of (i) the greater of (a) Prime Rate (as defined in the Third Amendment) and (b) 7.50% plus (ii) 3.50%. At the Company's option, 2.00% of the interest due on any applicable interest payment date during the interest-only period may be paid in-kind by adding such amount to the then outstanding principal balance of the Term Loans. The Company also owes an additional fee equal to 4.375% of the funded amount of the Term Loans, or $1.0 million (such additional fee, the "Final Fee") at maturity. The Company is accreting up to this Final Fee premium with a charge against interest expense on the accompanying condensed consolidated statements of operations. The Term Loans may be voluntarily prepaid in full (but not partially) at any time, upon at least seven business days’ prior notice. In connection with any voluntary prepayment or satisfaction of the Term Loans prior to the maturity date (including any acceleration), the Company will pay all accrued and unpaid interest and all other amounts due in connection with the Term Loans, together with (x) a prepayment fee (the “Prepayment Fee”) equal to: (i) 1.0% of the principal amount of the Term Loans prepaid if the payment is made after January 1, 2026 but on or before January 1, 2027; or (ii) 0% of the principal amount of the Term Loans prepaid if the payment is made after January 1, 2027 through maturity, and (y) the Final Fee. The Term Loans will be mandatorily prepaid upon a change in control
of the Company, or upon any early termination/acceleration of the Term Loans. In the event of a mandatory prepayment of the Term Loans, the Company shall be required to pay the Prepayment Fee (if applicable), as well as the Final Fee. The Third Amendment was treated as a modification for accounting purposes.
The Third Amendment contains various financial covenants and customary representations and warranties and affirmative and negative covenants, subject to exceptions as described in the Third Amendment. The Company's ability to comply with the covenants under the Third Amendment may be adversely affected by events beyond its control. If the Company is unable to comply with the covenants under the Third Amendment, it would pursue all available cure options in order to regain compliance. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. As of September 30, 2026, the Company was in compliance with all covenants under the Third Amendment.
In connection with the execution of the Third Amendment, on January 2, 2024, the Company issued a warrant to purchase 19,109 shares of the Company’s common stock. The warrant is equity-classified with a fair value of $0.2 million at issuance, which was treated as a debt issuance cost and is being amortized through interest expense over the remaining contractual term of the Term Loans. For additional information, see Note 11.
The effective interest rate used to amortize the debt issuance cost relating to these warrants is 11.0% as of September 30, 2026. As of September 30, 2026, the outstanding balance of the Term Loans was $9.1 million, net of aggregate unamortized issuance costs, discounts and premiums of $0.4 million. For both of the nine months ended September 30, 2026 and 2025, interest expense on the Term Loans, including paid-in-kind interest, amounted to $0.7 million.

At the closing of the acquisition described in Note 17, the Company will be required to repay the Term Loans in full,
together with the Final Fee, and to terminate the Loan Agreement.

The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. and contains customary representations and warranties and covenants, subject to customary carve outs, and initially included financial covenants related to liquidity and sales of Triferic.

The following table reflects the schedule of principal payments on the Term Loans as of September 30, 2026 (table in thousands):
YearPrincipal Payments
2026 (Remaining)$— 
20273,891 
20284,244 
2029 (Inclusive of Final Fee)1,338 
Total Debt Maturities9,473 
Unamortized Issuance Costs and Discount(423)
Total Debt Maturities, net of Unamortized Issuance Costs and Discount9,050 
Less: Current Portion of Term Loans(2,829)
Term Loans, net$6,221 
16. Insurance Financing Note Payable
On June 3, 2025, the Company entered into a short-term note payable with a principal amount of $0.7 million, bearing interest at a rate of 7.14% per annum to finance various insurance policies, which required an upfront payment of $0.2 million. Principal and interest payments related to this note began on July 3, 2025 and were paid in 10 equal monthly payments of $0.1 million, with the final payment paid on April 3, 2026.
On June 4, 2024, the Company entered into a short-term note payable with a principal amount of $0.7 million, bearing interest at a rate of 7.89% per annum to finance various insurance policies, which required an upfront payment of $0.2 million. Principal and interest payments related to this note began on July 3, 2024 and were paid in 10 equal monthly payments of $0.1 million, with the final payment paid on April 3, 2025.
14


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
17. Subsequent Events

On November 2, 2026, Rockwell Medical, Inc. entered into an Equity and Asset Purchase Agreement (the “Purchase Agreement”) with Vantive Limited (“Vantive”) pursuant to which the Company agreed to acquire Vantive's hemodialysis concentrates, hemodialysis machines, water treatment systems, and related consumables and technical services business, including Vantive's manufacturing campus located in Medolla, Italy. The acquisition is expected to significantly expand the Company's product portfolio, manufacturing capabilities and geographic reach. The transaction includes the acquisition of Gambro Dasco S.p.A. and Vantive Korea Incorporated and specified business assets and liabilities in other jurisdictions, subject to specified exclusions and possible deferred local transfers.

The aggregate base purchase price is $125.0 million, subject to customary working capital and other purchase price adjustments. The transaction is expected to be financed through two seller-provided term loans totaling $100.0 million and a $25.0 million convertible note to be issued to an affiliate of Vantive. In addition, the Purchase Agreement provides for contingent consideration of up to $45.0 million payable upon the achievement of specified revenue and EBITDA milestones. The Company may replace all or a portion of the seller term loans with qualifying third-party debt financing. The seller financing will become effective at closing; it does not provide cash for the Company’s pre-closing operations or transaction expenses. The contingent consideration comprises up to $25.0 million of EBITDA-based payments over eight full fiscal years after closing and two potential $10.0 million revenue-based payments, generally over five full fiscal years after closing, with a possible sixth-year extension for the second revenue milestone. Revenue earnout payments are subject to an annual payment limitation and may roll forward; specified unpaid amounts bear interest in addition to the $45.0 million maximum.

The unsecured convertible note will mature six years after closing, be subordinated in right of payment to specified senior debt and bear interest at 3.0% per annum payable in kind and will be convertible into shares of common stock at an initial conversion price of $14.94 per share, with the conversion price increasing on the same basis as ordinary PIK interest so that such interest does not increase the shares issuable in respect of the original principal. Subject to the note’s terms and applicable Nasdaq rules, issuances, together with other issuances required to be aggregated, may not exceed 19.99% of either the shares of common stock or voting power outstanding immediately before execution of the Purchase Agreement unless stockholder approval is obtained. The term loans will be secured by a lien on substantially all of the assets of the Company and its domestic subsidiaries and will mature on the sixth anniversary of the closing. The two initially $50.0 million tranches will bear interest at Term SOFR plus initial margins of 5.50% and 7.00%, respectively, increasing by 0.75 percentage points annually. Interest is payable monthly, although the Company may elect, subject to specified conditions, to capitalize interest on the first tranche at an additional 0.50% annual rate. The loans are subject to mandatory prepayments, restrictive covenants and customary events of default. Incurrence of the seller financing requires the consent of DaVita under the Securities Purchase Agreement described in Note 11, and at the closing the Company will repay in full and terminate the Loan Agreement described in Note 15.

The transaction is subject to customary closing conditions, including regulatory approvals and delivery of specified audited financial statements, completion of specified separation activities, execution of definitive transition services and manufacturing and supply agreements, and other conditions set forth in the Purchase Agreement, and is expected to close in mid-2027. The Purchase Agreement provides for an outside date of November 1, 2027, subject to extension in specified circumstances as provided therein. The Company is evaluating the accounting effects of the transaction and the financial impact of the acquisition cannot yet be reasonably estimated. The Company expects to incur additional transaction, financing and integration-related costs associated with the proposed acquisition.
15


Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes in “Item 1. Condensed Consolidated Financial Statements”. References in this report to “Rockwell,” the “Company,” “we,” “our” and “us” are references to Rockwell Medical, Inc. and its subsidiaries.
Forward-Looking Statements
We make forward-looking statements in this report and may make such statements in future filings with the U.S. Securities and Exchange Commission ("SEC"). We may also make forward-looking statements in our press releases or other public or shareholder communications. Our forward-looking statements are subject to risks and uncertainties and include information about our current expectations and possible or assumed future results of our operations. When we use words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” “is focused on” or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. Our forward looking statements also include, without limitation, statements about the proposed acquisition described in Note 17 to the condensed consolidated financial statements, including the expected timing and completion of the acquisition, its financing, its anticipated benefits and our ability to integrate the acquired business; our liquidity and capital resources; our ability to continue as a going concern; the size of the hemodialysis concentrates market opportunity; our ability to successfully execute on our business strategy, including our commercial focus; our ability to raise additional capital; our ability to successfully implement certain cost containment and cost-cutting measures; our ability to achieve and maintain profitability and statements regarding our anticipated future financial condition, operating results, cash flows and business plans.
While we believe our forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements, which are based on information available to us on the date of this report or, if made elsewhere, as of the date made. Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors that might cause such a difference include, without limitation, the risks and uncertainties discussed in this report, “Item 1A — Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, Part II, Item 1A, “Risk Factors” in this report, and from time to time in our other reports filed with the SEC.
Other factors not currently anticipated may also materially and adversely affect our results of operations, cash flow and financial position. There can be no assurance future results will meet expectations. Forward-looking statements speak only as of the date of this report and we expressly disclaim any intent to update or alter any statements whether as a result of new information, future events or otherwise, except as may be required by applicable law.
Overview
Rockwell is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide.
Rockwell is a supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. This represents a large market opportunity for which we believe Rockwell's products are well-positioned to meet the needs of patients.
We currently operate in one market segment, the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including dialysis concentrates and other ancillary products used in the dialysis process. Rockwell currently serves approximately 300 customers, highlighted by all five of the leading dialysis providers in the United States, including Fresenius Medical Care North America ("Fresenius") and DaVita Inc. ("DaVita"). Rockwell's customer mix is diverse, with most customer sales concentrations under 10%. Dialysate concentrates and other ancillary products accounted for 100% of our revenue for the nine months ended September 30, 2026, of which approximately 85% was to distributors and customers for use in the United States.
Our commercial organization supports the Company's vision to focus its efforts on driving Rockwell Medical toward
sustainable profitability. Our commercial team is focused on expanding revenue within our current customer base and seeking to grow revenue through the addition of new accounts to increase Rockwell's overall market share within the hemodialysis concentrates sector. We focus on creating long-term partnerships with customers, securing appropriate pricing for our products, and delivering high-quality product to our customers for use with their patients.
Rockwell's products are vital to vulnerable patients with end-stage kidney disease. We are an established leader in manufacturing and delivering high-quality hemodialysis concentrates and dialysates, along with certain ancillary products, to dialysis providers and distributors in the United States and abroad. Rockwell provides the hemodialysis community with products controlled by a Quality Management System regulated by the U.S. Food and Drug Administration ("FDA"). Rockwell is ISO 13485 Certified and adheres to current Good Manufacturing Practices ("cGMP") and Association for Advancement of Medical Instrumentation ("AAMI") standards. Rockwell manufactures hemodialysis concentrates at its facilities in Michigan and Texas, and manufactures its dry acid concentrate mixers at its facility in Iowa.
Rockwell delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service.
Rockwell continues to upgrade its manufacturing equipment to streamline production and improve margins, has renegotiated pricing with key suppliers, and has entered into several multi-year customer purchase agreements.
On September 18, 2023, Rockwell and DaVita entered into an Amended and Restated Products Purchase Agreement (the "Amended Agreement"), under which the Company supplies DaVita with certain dialysis concentrates. The term of the Amended Agreement was scheduled to expire on December 31, 2024. Prior to the expiration, the Company received written notice from DaVita that DaVita intended to extend the term of the Amended Agreement through December 31, 2025 (the "Extension Term"). Subsequently, DaVita indicated that it would completely transition to another supplier, subject to further discussions between Rockwell and DaVita. Additionally, DaVita agreed to quarterly, non-refundable payments totaling $2.0 million to ensure supply continuity for products purchased during the year ended December 31, 2025. These quarterly, non-refundable payments of $1.7 million were recorded as revenue during the nine months ended September 30, 2025. While DaVita did significantly reduce its product purchases from Rockwell, it did not completely transition its business to a different supplier. On December 23, 2025, the Company and DaVita entered into a second amendment (the "Second Amendment") to the Amended Agreement which extended the term of the Amended Agreement by one additional year to December 31, 2026 (the "Second Extension Term"). The Second Amendment also provides for a price increase on the products sold under the Amended Agreement for the Second Extension Term. The Second Extension Term expires on December 31, 2026, and the Amended Agreement will terminate on that date unless it is further extended.
Reverse Stock Split
On May 8, 2026, we received notice from Nasdaq that we did not meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(a)(2), and we were provided a compliance period through November 4, 2026. On July 1, 2026, we effected a one-for-ten reverse stock split of our common stock to regain compliance with Nasdaq Capital Market's $1.00 minimum bid price requirement. On July 16, 2026, we received notice from Nasdaq that we had regained compliance with the minimum bid price requirement and that Nasdaq closed the matter. All share and per-share amounts in this report have been retrospectively adjusted to reflect the split for all periods presented. See Note 11 to the condensed consolidated financial statements.
16


Results of Operations for the Three Months Ended September 30, 2026 and 2025
The following table summarizes our operating results for the periods presented below (dollars in thousands):
Three Months Ended September 30,
2026% of Revenue2025% of Revenue% Change
Net Sales$19,122 $15,927 20 %
Cost of Sales16,011 84 %13,655 86 %17 %
Gross Profit3,111 16 %2,272 14 %37 %
Research and Product Development114 1 %— — %— %
Selling and Marketing572 3 %531 3 %8 %
General and Administrative3,799 20 %3,325 21 %14 %
Transaction-related expenses847 4 %— — %— %
Operating Loss$(2,221)(12)%$(1,584)(10)%40 %
Net Sales
During the three months ended September 30, 2026, net sales were $19.1 million compared to net sales of $15.9 million during the three months ended September 30, 2025. The increase of $3.2 million was primarily driven by $1.2 million of sales to new customers in the Western United States as well as additional sales and price increases to existing customers. Non-Product revenue was not material for either period. DaVita represented 7% and 12% of net sales for the three months ended September 30, 2026 and 2025, respectively.
Cost of Sales and Gross Profit

Cost of sales for the three months ended September 30, 2026 was $16.0 million, resulting in gross profit of $3.1 million for the three months ended September 30, 2026, compared to cost of sales of $13.7 million and a gross profit of $2.3 million for the three months ended September 30, 2025. The gross profit increase of $0.8 million was primarily due to (i) a $0.6 million increase from higher volume, and (ii) $0.5 million from restructuring cost in the three months ended September 30, 2025 related to the closure of the Company's Greer, South Carolina manufacturing facility, partially offset by a $0.4 million decline due to a price adjustment for DaVita purchases for the three months ended September 30, 2025 that did not repeat in 2026.
Selling and Marketing Expense
Selling and marketing expenses for the three months ended September 30, 2026 were $0.6 million compared to $0.5 million during the three months ended September 30, 2025.
General and Administrative Expense
General and administrative expenses were $3.8 million for the three months ended September 30, 2026, compared to $3.3 million for the three months ended September 30, 2025. The increase of $0.5 million was driven by additional administrative costs to support growth.
Transaction-related expenses
Transaction-related expenses were $0.8 million for the three months ended September 30, 2026, consisting of legal, consulting and other professional fees incurred in connection with a pending acquisition (see Note 17 to the condensed consolidated financial statements included elsewhere in this Form 10-Q). There were no comparable expenses during the three months ended September 30, 2025. We expect to incur additional transaction-related expenses in future periods as we work toward completing this acquisition.
17


Other Expense
Total other expense of $0.1 million and $0.2 million for the three months ended September 30, 2026 and 2025, respectively, was comprised primarily of cash interest expense of $0.2 million in each period related to our debt facility (See Note 15 to the condensed consolidated financial statements included elsewhere in this Form 10-Q). The interest expense for the three months ended September 30, 2026 was partially offset by $0.1 million of realized gains on available-for-sale investments.
18


Results of Operations for the Nine Months Ended September 30, 2026 and 2025
The following table summarizes our operating results for the periods presented below (dollars in thousands):
Nine Months Ended September 30,
2026% of Revenue2025% of Revenue% Change
Net Sales$54,238 $50,912 7 %
Cost of Sales44,987 83 %43,095 85 %4 %
Gross Profit9,251 17 %7,817 15 %18 %
Research and Product Development154 — %— — %— %
Selling and Marketing1,716 3 %1,814 4 %(5)%
General and Administrative11,296 21 %10,296 20 %10 %
Transaction-related expenses847 2 %— — %— %
Operating Loss$(4,762)(9)%$(4,293)(8)%11 %
Net Sales
During the nine months ended September 30, 2026, net sales were $54.2 million compared to net sales of $50.9 million during the nine months ended September 30, 2025. The increase of $3.3 million was primarily due to (i) an increase of $3.8 million from new customers in the Western United States, as well as (ii) $4.6 million from increased sales and price increases to existing customers and sales to new customers, partially offset by a $4.7 million reduction in sales to DaVita, which included a $1.7 million price adjustment in 2025 that did not repeat in 2026. Non-product revenue was $0.3 million for the nine months ended September 30, 2025 from the recognition of the remaining deferred revenue associated with Triferic licenses. DaVita represented 7% and 17% of net sales for the nine months ended September 30, 2026 and 2025, respectively.
Cost of Sales and Gross Profit

Cost of sales for the nine months ended September 30, 2026 was $45.0 million, resulting in gross profit of $9.3 million for the nine months ended September 30, 2026, compared to cost of sales of $43.1 million and a gross profit of $7.8 million for the nine months ended September 30, 2025. The gross profit increase of $1.5 million was primarily due to (i) a $1.8 million increase as a result of lower manufacturing costs due to a decrease in production headcount, (ii) $0.7 million from higher volumes, and (iii) $0.7 million of restructuring expense related to the closure of the Company's Greer, South Carolina manufacturing facility during the nine months ended September 30, 2025, partially offset by (i) a $1.7 million decline due to a price adjustment for DaVita purchases for the nine months ended September 30, 2025 that did not repeat in 2026 and (ii) a decrease of $0.1 million in gross profit related to the recognition of remaining deferred revenue associated with Triferic licenses in the nine months ended September 30, 2025.
Selling and Marketing Expense
Selling and marketing expenses for the nine months ended September 30, 2026 were $1.7 million compared to $1.8 million during the nine months ended September 30, 2025. The decrease was due primarily to $0.1 million of lower compensation expense as a result of lower headcount.
General and Administrative Expense
General and administrative expenses were $11.3 million for the nine months ended September 30, 2026, compared to $10.3 million for the nine months ended September 30, 2025. The increase of $1.0 million was driven by $0.5 million of additional administrative cost to support growth, $0.4 million of higher compensation expense and $0.2 million of asset disposal costs related to the closure of the Greer facility.
19


Transaction-related expenses
Transaction-related expenses were $0.8 million for the nine months ended September 30, 2026, consisting of legal, consulting and other professional fees incurred in connection with a pending acquisition (see Note 17 to the condensed consolidated financial statements included elsewhere in this Form 10-Q). There were no comparable expenses during the nine months ended September 30, 2025. We expect to incur additional transaction-related expenses in future periods as we work toward completing this acquisition.
Other Expense
Total other expense of $0.3 million and $0.5 million for the nine months ended September 30, 2026 and 2025, respectively, was driven primarily by interest expense of $0.6 million in each period related to our debt facility (See Note 15 to the condensed consolidated financial statements included elsewhere in this Form 10-Q). The interest expense for the nine months ended September 30, 2026 was partially offset by $0.4 million of realized gains on available-for-sale investments.
Liquidity and Capital Resources
As of September 30, 2026, we had approximately $22.5 million of cash, cash equivalents and investments available-for-sale, and net working capital of $22.1 million. Based on the currently available net working capital along with the expectation of management of its ability to execute on its operational plans as discussed below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.
The liquidity information above does not consider any impacts of the pending acquisition described in Note 17 to the condensed consolidated financial statements.
Additionally, the Company's operational plans include raising capital, if needed, by using the $13.1 million remaining availability under its at-the-market ("ATM") facility or other methods or forms of financings. The proposed acquisition described in Note 17 may limit our ability to use the ATM facility or conduct other registered offerings until the required historical financial statements of the acquired business and related pro forma financial information have been filed. Accordingly, the remaining ATM capacity should not be viewed as committed or immediately available funding. See Part II, Item 1A, “Risk Factors.” When sales under the ATM are permitted, we have the ability to control the timing and floor price at which capital is raised.
The actual amount of cash that we will need to execute our business strategy is subject to many factors, including, but not limited to, the costs associated with our manufacturing and transportation operations repayment of our existing debt, transaction and financing expenses, and the working capital, transition and integration requirements associated with the proposed acquisition.
We may elect to raise capital in the future through one or more of the following: (i) equity and debt raises through the equity and capital markets, though there can be no assurance we will be able to secure additional capital or funding on acceptable terms, or if at all; and (ii) strategic transactions, including potential alliances and collaborations focused on markets outside the United States, as well as potential combinations (including by merger or acquisition) or other corporate transactions. Our ability to pursue the alternatives described in clause (i) is subject to the limitations described above and in Part II, Item 1A, “Risk Factors,” including potential limitations on registered offerings pending the filing of the financial statements and pro forma financial information of the acquired business required by SEC rules and the limitation on incurring indebtedness under our Securities Purchase Agreement with DaVita.
We believe our ability to fund our activities in the long term will be highly dependent upon (i) our ability to execute on the growth strategy of our hemodialysis concentrates business and maintain sales with existing customers, (ii) our ability to achieve sustained profitability and (iii) our ability to identify, develop, in-license, or acquire new products in developing our product portfolio. All of these strategies are subject to significant risks and uncertainties such that there can be no assurance we will be successful in achieving them. If we are unsuccessful in executing our business plan and we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations. Even if we are able to raise sufficient capital, such financings may only be available on unattractive terms, or result in significant dilution of stockholders’ interests and, in such event, the market price of our common stock may decline.
If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all. In addition, any debt financing is limited by the terms of our Securities Purchase Agreement with DaVita. Specifically, until DaVita holds less than 50% of its original investment in the Company's Series
X Convertible Preferred Stock, the Company may only incur additional debt in the form of a purchase money loan, a working capital line of up to $5.0 million or to refinance existing debt, unless DaVita consents. The seller financing we expect to incur
in connection with the acquisition described in Note 17 to the condensed consolidated financial statements requires DaVita's
consent.

The Company is subject to certain covenants and cure provisions under its Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP. As of September 30, 2026, the Company was in compliance with all covenants. On January 2, 2024, the Loan Agreement was amended to include, among other things, an interest-only period for 30 months, or up to 36 months if certain conditions are met, and extend the maturity date to January 1, 2029 (See Note 15 to the accompanying condensed consolidated financial statements).

On November 2, 2026, we entered into the Purchase Agreement described in Note 17 to the condensed consolidated
financial statements, under which we agreed to acquire Vantive's in-center hemodialysis business for a base purchase price of
$125.0 million, subject to adjustment, plus contingent consideration of up to $45.0 million. We expect to fund the closing
consideration with $100.0 million of secured term loans and a $25.0 million convertible note to be provided by affiliates of
Vantive, and we may elect to replace all or a portion of the term loans with third-party debt financing. Incurring that
indebtedness requires DaVita's consent under our Securities Purchase Agreement, and at the closing we will be required to
repay our existing term loans in full and terminate the Loan Agreement. We also expect to incur significant transaction,
financing and integration costs before and after the closing, and we incurred $0.8 million of transaction-related costs during the
three and nine months ended September 30, 2026. The acquisition is expected to close in mid-2027. See Part II, Item 1A, “Risk
Factors.” The seller financing principally funds the acquisition consideration; we will need separate liquidity for the
existing-loan payoff, closing expenses and the acquired business’s working capital and integration needs. The Purchase
Agreement permits a separate asset-based revolving facility of up to $50.0 million, subject to specified terms, but does not
itself commit any third party to provide that facility. On November 3, 2026, we withdrew our previously issued 2026 guidance
for net sales, gross margin, Adjusted EBITDA and operating cash flow in light of expected acquisition-related transaction and
financing expenses.

The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, changes in U.S. trade policies, including tariffs and other trade restrictions or the threat of such actions, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the Middle East conflicts and other political tensions, and the occurrence of natural disasters and public health crises. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.

On July 4, 2025, the U.S. enacted P.L. 119-21, a U.S. federal statute passed by the 119th United States Congress that includes tax and spending policies (the “Act”), which contains a broad range of tax reform provisions affecting businesses, including extending or reinstating certain provisions of the 2017 Tax Cuts and Jobs Act, tax relief measures, modifications of certain energy tax credits granted under the Inflation Reduction Act and limits on various tax deductions, among other key provisions. The Company evaluated the Act and concluded it will not have a material impact on its condensed consolidated financial statements.
Cash Provided By (Used In) Operating Activities
Net cash provided by operating activities was $0.4 million for the nine months ended September 30, 2026 compared to net cash used in operating activities of $3.0 million for the nine months ended September 30, 2025. The increase in cash provided by operating activities during the current period as compared to the prior period was primarily due to a decrease in cash used in changes in current balance sheet accounts in the ordinary course of business of approximately $4.5 million, partially offset by an increase in net loss of approximately $0.3 million, and a decrease in non-cash adjustments of approximately $0.9 million.
Cash Provided By (Used In) Investing Activities
Net cash provided by investing activities was $1.1 million during the nine months ended September 30, 2026 compared to net cash used in investing activities of $4.4 million for the nine months ended September 30, 2025. Net cash provided by investing activities during the nine months ended September 30, 2026 was primarily driven by net cash proceeds from purchases and sales of our available-for-sale investments of $2.7 million and purchases of property and equipment, net of $1.6 million.
Cash (Used In) Provided By Financing Activities

Net cash used in financing activities was $1.6 million during the nine months ended September 30, 2026 compared to net cash provided by financing activities of $5.3 million for the nine months ended September 30, 2025. Net cash used in financing activities during the nine months ended September 30, 2026 was primarily due to (i) the cash paid in connection with the Evoqua Asset Acquisition deferred consideration obligation of $1.0 million, (ii) $0.4 million of payments on finance lease liabilities and (iii) $0.3 million of payments under the insurance financing note payable. Net cash provided by financing activities during the nine months ended September 30, 2025 was primarily due to proceeds from the issuance of common stock under the ATM facility of $7.8 million, partially offset by (i) the cash paid in connection with the Evoqua Asset Acquisition deferred consideration obligation of $1.6 million, (ii) $0.5 million of payments under the insurance financing note payable and (iii) $0.4 million of payments on finance lease liabilities.
Contractual Obligations and Other Commitments
Due to the contract-intensive nature of the Company's business, the Company has been and may in the future become involved in disputes or legal actions with its contract counterparties, which could have a negative impact on the Company's business, results of operations or financial condition. See Note 13 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for additional disclosures. In 2026, we extended our Grapevine, Texas facility lease through February 2031 (lease liability of approximately $2.5 million) and entered into a five-year lease for office space in Newtown Square, Pennsylvania commencing October 1, 2026 (total fixed payments of approximately $1.6 million). See Note 14. Other than these leases and the obligations we will incur in connection with the acquisition described in Note 17 to the condensed
consolidated financial statements, there have been no material changes from the contractual obligations and other commitments disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.
Critical Accounting Policies and Significant Judgments and Estimates

Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2025.
Recently issued and adopted accounting pronouncements:
See Note 3 to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a discussion of recently adopted accounting pronouncements and those the Company is evaluating.
Item 3.  Quantitative and Qualitative Disclosures about Market Risk

Per §229.305 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in §229.10(f)(1) of Regulation S-K, is not required to provide the disclosure required by this Item.
Item 4.  Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and such information is accumulated and communicated to our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) as
appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognized that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management was necessarily required to apply its judgment in evaluating the cost‑benefit relationship of possible controls and procedures.
Under the supervision of and with the participation of our management, including the Company’s Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as such terms are defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2026.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1.  Legal Proceedings
We may be involved in certain routine legal proceedings from time to time before various courts and governmental agencies. We cannot predict the final disposition of such proceedings. We regularly review legal matters and record provisions for claims considered probable of loss. The resolution of these pending proceedings is not expected to have a material effect on our operations or consolidated financial statements in the period in which they are resolved.
Item 1A. Risk Factors
Our business is subject to various risks, including those described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Except as set forth below, there have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2025 under "Item 1A - Risk Factors."

On November 2, 2026, we entered into an Equity and Asset Purchase Agreement (the “Purchase Agreement”) with Vantive Limited (“Vantive”) pursuant to which we have agreed to acquire Vantive’s in-center hemodialysis business (the “acquired business”), consisting of hemodialysis concentrates, water treatment systems, hemodialysis monitors and related consumables and technical services in 35 jurisdictions, including the United States (the “Vantive Transaction”). The Vantive Transaction, if completed, would significantly increase the scale, geographic reach and complexity of our business and expose us to additional risks and uncertainties. Accordingly, we are supplementing the risk factors previously disclosed in our Annual Report on Form 10-K with the following risk factors relating to the Vantive Transaction. The risks described below should be read together with the other risk factors and information contained in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K and our other filings with the SEC. The terms of the Vantive Transaction and the related seller financing are summarized in Note 17 to the condensed consolidated financial statements included in this report and in our Current Report on Form 8-K filed on November 3, 2026.

We may not complete the Vantive Transaction on the anticipated terms or timetable, or at all, and we do not have a financing condition to our obligation to complete the transaction.

Completion of the Vantive Transaction is subject to a number of conditions, including required regulatory approvals, specified pre-closing restructuring and separation activities, completion of the separation of Vantive’s information technology systems from those of Baxter International Inc. (“Baxter”), its former parent, delivery of audited financial statements of the acquired business for 2025 and 2026, execution of definitive transition services and manufacturing and supply agreements, and other closing conditions. Certain of these matters depend on Vantive or third parties and could delay or prevent completion of the transaction. Taking into account these conditions and the anticipated separation timetable, we currently expect the closing to occur in mid-2027. Either party may terminate the Purchase Agreement if the closing has not occurred by November 1, 2027,
subject to two 90-day extensions if only regulatory approvals and specified other conditions remain outstanding, and further extension in certain enforcement proceedings. The closing therefore could be delayed into April 2028 or later, and expiration of the outside date does not automatically terminate the Purchase Agreement.

We do not have a financing condition to our obligation to close the Vantive Transaction, and the Purchase Agreement provides for specific performance in appropriate circumstances. Accordingly, if the applicable closing conditions are satisfied, we may be required to close the transaction notwithstanding developments that do not give rise to a contractual right not to close. In addition, under the Securities Purchase Agreement relating to our Series X Convertible Preferred Stock, we need the consent of DaVita Inc. (“DaVita”), a customer and the holder of that preferred stock, to incur the seller financing described below. Obtaining that consent is not a condition to our obligation to complete the Vantive Transaction. If DaVita does not consent, we would need to fund the purchase price from other sources, which may not be available on acceptable terms or at all, or complete the Vantive Transaction in breach of the Securities Purchase Agreement, which could expose us to claims by DaVita and adversely affect our commercial relationship with DaVita.

Until closing, management will continue to devote substantial time and resources to the transaction. If the transaction is delayed or not completed, we may incur significant advisory, financing, legal, integration-planning and other costs, as well as management distraction, without realizing the anticipated benefits of the transaction.

The Vantive Transaction will substantially increase our indebtedness and liquidity requirements and could materially reduce our financial flexibility.

We expect to fund the $125 million base purchase price with seller financing provided by affiliates of Vantive, consisting of $100 million of secured term loans, subject to adjustment, and a $25 million convertible note, except to the extent we elect to replace term loans with qualifying third-party financing. The term loans will be secured by a lien on substantially all of our assets and those of our domestic subsidiaries, including the assets of our existing concentrates business, and by a pledge of the equity of our subsidiaries, will bear interest at Term SOFR plus initial margins of 5.50% and 7.00% for the two tranches, respectively, increasing by 0.75 percentage points annually, and will mature six years after closing with no regular scheduled principal amortization, but subject to mandatory prepayments, including potential tax-related catch-up payments after the fifth anniversary. Interest is payable monthly; subject to specified conditions, interest on the first tranche may be paid in kind at an additional 0.50% annual rate, increasing the principal that must ultimately be repaid. We currently expect to service this debt primarily from the cash flow of the acquired business, which we do not yet control and which has not operated as a standalone company, and our existing operations alone may not generate sufficient cash flow to service it. We may replace all or a portion of the term loans with qualifying third-party financing, and the seller term loans will not be reduced for any shortfall in replacement-financing proceeds actually paid to Vantive. We remain obligated to deliver the full closing consideration if the applicable closing conditions are satisfied and Vantive provides the required seller financing. Vantive will retain the cash of the acquired business through the closing, and any cash left in the acquired entities at the closing will increase the purchase price and the principal of the term loans; in jurisdictions where the acquired business is transferred by asset sale, Vantive will also retain receivables that arose before the closing. As a result, we will need to fund the working capital of the acquired business from the closing.

Our liquidity requirements in connection with the transaction may be significant and may include integration and stand-up costs, payroll, working capital, supplier payments, transition costs, professional fees and other expenses associated with operating the acquired business independently from Vantive. We may also be required to replace certain letters of credit, surety bonds, guarantees and other credit support or, in certain circumstances, provide cash collateral or other credit support, which could further reduce our available liquidity and borrowing capacity.

Our increased indebtedness will require us to devote cash to interest and other debt-service obligations and could limit funds available for our businesses, capital expenditures or other strategic opportunities. The financing arrangements also contain restrictions on our operations and financing activities, including requirements to apply certain proceeds from equity issuances to repay indebtedness, and contain events of default, including cross-defaults, judgment defaults and the delisting of our common stock from Nasdaq, upon which the lender could accelerate the term loans and foreclose on the collateral, including the assets of our existing business. If our actual liquidity requirements exceed our expectations, we may need additional financing, which may not be available or may be available only on unfavorable terms. Vantive and its affiliates will simultaneously be our seller, our secured lender, the holder of the convertible note and a potential significant stockholder, a principal supplier of the acquired business and our transition services provider, and their interests in those capacities may differ from ours, including in any dispute under the Purchase Agreement.

Our ability to raise capital through registered offerings, including under our at-the-market facility, may be limited by the need to file required financial statements of the acquired business and related pro forma financial information.

The Vantive Transaction may require historical financial statements of the acquired business and related pro forma financial information in connection with registered offerings. The requirements depend on the acquisition’s significance, the type and timing of the offering and, for use of an existing shelf registration statement before closing, whether the probable acquisition represents a fundamental change. Until the required information is available and filed, our ability to raise capital through the ATM facility or other registered offerings may be limited. Vantive is required to prepare and deliver specified audited and interim financial statements as promptly as practicable, but there can be no assurance they will be available when we need to raise capital. These limitations may continue after closing. Private placements could also be more costly or difficult to arrange if purchasers cannot promptly resell their securities under an effective registration statement.

In addition, our ability to incur debt is limited by the consent right of DaVita described above, and while the seller term loans remain outstanding, net proceeds of equity issuances subject to the mandatory-prepayment provisions generally must first be applied in full to the second tranche and, after that tranche is repaid, 65% of the remaining proceeds must be applied to the first tranche, subject to specified exceptions. This limits the proceeds available to fund our operations. If we need additional capital during this period, we may be unable to obtain it or may obtain it only on unfavorable terms, which could require us to curtail investment in the acquired business or in our existing operations.

The historical financial information for the acquired business may not be indicative of its performance as a standalone business, and we may not realize the anticipated strategic and financial benefits of the Vantive Transaction.

The acquired business historically has operated as part of Vantive’s broader organization and has not operated or historically been reported as a separate standalone business. Accordingly, its historical financial information may not reflect all costs associated with operating independently, and actual operating costs, working capital requirements, capital requirements and financial results following closing may differ materially from historical amounts and from the assumptions used by us in evaluating the transaction. The base purchase price generally will not be reduced for deterioration in the acquired business’s operating performance after 2025. Separate closing adjustments apply, and a specified revenue-based adjustment applies if audited 2025 net revenue falls short of the unaudited amount provided to us by 20% or more, and the closing condition relating to the absence of a material adverse effect on the acquired business is subject to significant exceptions.

Our expectations regarding the transaction are based on assumptions regarding, among other things, future revenues, profitability, customer retention, market opportunities, integration costs, foreign currency exchange rates and working capital requirements. Prior to the transaction, commercial activities in certain markets were reduced or discontinued, including through decisions not to pursue certain tenders or renewals, and certain supplier relationships were affected by reduced forecasts, loss of exclusivity, disputes or renegotiations. The Purchase Agreement permits Vantive to continue certain of these portfolio optimization initiatives before the closing. We may not be able to restore affected relationships, successfully compete for future tenders or achieve historical or projected levels of revenue and profitability. If the acquired business performs differently from our expectations, we may fail to realize some or all of the anticipated benefits of the transaction.

The Vantive Transaction will significantly increase the complexity of our financial reporting, and we will depend on Vantive for the financial statements of the acquired business.

The acquired business has never been reported as a standalone company, and its historical financial statements are carve-out statements prepared by Vantive with allocations of shared costs. We will rely on Vantive and its auditors to deliver the audited and interim financial statements of the acquired business that we need to satisfy the closing conditions and our SEC reporting obligations, including the requirement to file historical and pro forma financial information after the closing, and delays or deficiencies in those statements could delay the closing or limit our access to the capital markets. After the closing, we will need to bring the acquired business within our internal control over financial reporting, implement controls over operations in multiple countries and currencies, and account for the Vantive Transaction, including any goodwill and intangible assets recognized, which may later be impaired. Material weaknesses, restatements or late filings could result, and a failure to deliver required financial reports to the lender could be an event of default under the term loans.

The Vantive Transaction will significantly increase the scale, geographic scope and complexity of our operations, and we may be unable to successfully integrate the acquired business.

The Vantive Transaction will substantially expand our international operations and add significant manufacturing, commercial, regulatory, supply-chain and employee operations, including through the acquisition of businesses in Italy and Korea and the transfer of additional businesses and assets across multiple jurisdictions.

Integration will require significant management attention and resources and will require us to integrate personnel, financial controls, information technology, regulatory processes, commercial relationships, manufacturing operations, supply chains and compliance functions across multiple jurisdictions. We also will need to establish or materially expand commercial, operational, financial, human resources, legal and compliance capabilities for portions of the acquired business that historically relied on Vantive’s broader organization. These demands could divert management attention from our existing business and cause the costs or difficulties of integration to exceed our expectations.

The separation of the acquired business from Vantive is complex, and we will continue to depend on Vantive and other third parties following closing.

The acquired business has not historically operated on a standalone basis. Prior to closing, Vantive is required to complete a reorganization to separate and allocate the assets, liabilities, contracts, employees, permits and other rights and operations comprising the acquired business. The Purchase Agreement provides us with certain protections, including approval rights over aspects of the Italian reorganization and limitations on certain changes to the agreed transaction perimeter.

Nevertheless, certain assets, permits and contractual rights may require deferred transfer or third-party consent, certain customer contracts cover both acquired and retained products, and certain supply arrangements, manufacturing know-how and support functions upon which the business relies are provided by Vantive, Baxter or other third parties, and certain of those arrangements, including the supply of a priming solution sold under a number of customer contracts, are scheduled to expire in early 2027 without an identified replacement source for all affected markets. Following closing, we also will rely on Vantive for transition services for initial terms of up to 18 months and for the manufacture and supply of certain products for fixed terms, after which we must have established replacement capabilities or qualified alternative sources. Definitive transition services and manufacturing and supply agreements and their service schedules and annexes remain to be completed in accordance with the agreed term sheets before closing; the services and supply arrangements have limited scope and will not replace every function historically provided by Vantive.

If these separation activities are delayed or incomplete, Vantive or other suppliers fail to perform, or we are unable to establish replacement capabilities or alternative sources within applicable transition periods, we may experience additional costs or disruptions in manufacturing, product availability, customer service, regulatory activities, financial reporting or other operations.

We may be unable to retain, transfer or successfully transition significant customer, distributor, supplier and other contractual relationships following the Vantive Transaction.

The acquired business operates through customer, distributor, supplier and other contractual relationships in multiple jurisdictions. Certain contracts may require consent, notice, separation, novation or other arrangements in connection with the transaction. The failure to obtain third-party consents generally will not constitute a failure of a closing condition under the Purchase Agreement. Although the Purchase Agreement provides for efforts to obtain required consents and alternative arrangements relating to certain contracts that cannot be transferred at closing, counterparties may not agree to an assignment, replacement agreement or alternative arrangement on existing terms or at all. Customers, distributors and suppliers may also choose not to continue their relationships with us or may seek different pricing or other commercial terms. Any loss or deterioration of significant commercial relationships could adversely affect the acquired business and our expected returns from the transaction.

We will assume significant liabilities associated with the acquired business, including liabilities that may be unknown, contingent or not fully quantified at closing.

Under the Purchase Agreement, we will acquire Gambro Dasco S.p.A. and Vantive Korea Incorporated with their historical liabilities and will assume liabilities to the extent related to the acquired business or transferred assets in other jurisdictions, other than liabilities specifically retained by Vantive. The assumed liabilities include liabilities that may be accrued or fixed, known or unknown, absolute or contingent, matured or unmatured or otherwise not fully determinable at closing. Some assumed liabilities may not have been identified or fully quantified during diligence or may exceed amounts
reflected in the financial information available to us. The acquired business was owned by Baxter until early 2025, and Vantive’s representations regarding periods before its ownership are limited. Although Vantive has agreed to retain specified liabilities, contractual allocation of responsibility may not prevent claims from being asserted against us or acquired entities under applicable law. We could therefore incur costs defending against such claims and be required to seek recovery from representation and warranty insurance or Vantive where contractual indemnification is available.

Our remedies for certain liabilities and breaches relating to the acquired business will be limited, and we may bear losses that are not covered by representation and warranty insurance or otherwise recoverable from Vantive.

Except in specified circumstances, including fraud, Vantive’s representations and warranties under the Purchase Agreement generally will not survive closing. Our recourse for losses resulting from a breach or inaccuracy of those representations and warranties generally will be against a representation and warranty insurance policy that we expect to have in effect at closing. We have received a conditional binder for such insurance, but the final terms and scope of coverage remain subject to negotiation and have not yet been finalized. The Purchase Agreement requires us to use commercially reasonable efforts to cause coverage to become effective at closing; however, the availability or binding of the policy is not a condition to closing.

If obtained, the representation and warranty insurance policy will be subject to coverage limits, a retention, exclusions and other terms and conditions that could limit our ability to recover losses. The final scope of coverage, including applicable exclusions, may differ from the coverage currently contemplated. Certain matters may not be covered, and losses could exceed applicable policy limits or otherwise fall outside the scope of coverage. Accordingly, there can be no assurance that the policy ultimately obtained will provide coverage for all losses arising from breaches or inaccuracies of Vantive’s representations and warranties.

Vantive has separately agreed to indemnify us for certain excluded or retained liabilities. Recovery with respect to certain indemnification obligations, however, may require a final determination of the applicable claim, and amounts finally determined to be owed generally are subject first to setoff against outstanding seller term loans and then against the convertible note, with remaining amounts payable in cash. Our ability to collect amounts not satisfied by setoff will depend on Vantive’s creditworthiness. There can be no assurance that the representation and warranty insurance ultimately obtained, our setoff rights or direct recovery from Vantive will fully compensate us for losses associated with the acquired business or that the loans and convertible note will remain outstanding long enough for the setoff to occur.

Certain portions of the acquired business may not transfer to us at the initial closing and ultimately may not transfer at all.

Certain businesses in individual jurisdictions may not be capable of transfer at the initial closing because of regulatory approvals, permits, third-party consents, employee consultation requirements, entity formation requirements or other legal or operational impediments. In those circumstances, an affected business may remain legally held and operated by Vantive following the initial closing for our economic benefit and account pending a subsequent local closing, and we generally will bear the economic risks and benefits notwithstanding that we do not hold legal title.

If a local closing does not occur within the periods specified in the Purchase Agreement, the parties may be required to pursue alternative arrangements and, in certain circumstances, an affected business ultimately may not transfer to us, in which case the jurisdiction would be excluded from the Vantive Transaction and the principal amount of the term loans reduced by the value allocated to it, net of specified wind-down costs. Any delay in or inability to complete a local transfer could disrupt operations, reduce the geographic scope or revenues of the acquired business or reduce the anticipated benefits of the transaction.

Regulatory approvals for the Vantive Transaction may impose conditions that increase our costs or restrict the operation of the acquired business.

Completion of the Vantive Transaction requires regulatory approvals in certain jurisdictions, including clearance under Italian foreign investment (golden power) law, other foreign investment clearances and merger control clearance in certain countries. The Purchase Agreement restricts the conduct of the acquired business before closing and imposes specified pre-closing obligations on us. A breach of these covenants could delay or jeopardize the transaction or give rise to contractual liability. Applicable antitrust and foreign investment laws also limit pre-closing coordination and information sharing between us and Vantive; violations of these laws could delay or jeopardize the transaction or result in fines or other penalties. Regulatory
authorities may impose requirements, conditions, commitments, undertakings or restrictions in connection with such approvals. Although we are not required under the Purchase Agreement to accept a condition that constitutes a contractually defined Burdensome Condition, we may be required to accept requirements that do not reach that threshold. Such requirements could increase our costs, reduce our operating flexibility or reduce the anticipated benefits of the transaction.

The international expansion resulting from the Vantive Transaction will expose us to additional regulatory, compliance, tax, labor and other risks.

The Vantive Transaction will substantially expand our operations outside the United States and expose us to additional laws and regulations relating to medical devices and healthcare, anti-corruption, anti-money laundering, sanctions and trade controls, data privacy, environmental matters, employment and labor, taxation and other areas. We also will need to establish, integrate or expand compliance capabilities presently provided by or within Vantive’s larger organization. Failure to comply with applicable requirements could result in fines, penalties (including criminal penalties), taxes, remediation obligations, product restrictions, reputational harm or operational disruption. In addition, most of the revenue and costs of the acquired business are denominated in euros, Korean won and other currencies, while the term loans and the convertible note will be denominated in US dollars, so currency movements will affect our reported results and our ability to service that debt.

The products of the acquired business, including hemodialysis monitors and disposables, expose us to product liability, recall and regulatory risks greater than those of our existing concentrates business.

The acquired business manufactures and sells life-sustaining hemodialysis monitors and disposables used in dialysis clinics in many countries and is regulated by medical device authorities and notified bodies outside the United States. Certain products of the acquired business are already subject to ongoing field corrective actions, and products of this type may also be subject to additional corrective actions, product liability claims and regulatory enforcement actions. Although Vantive has agreed to retain specified pre-closing matters, we will assume specified operational responsibilities and liabilities, including responsibility for carrying out certain ongoing field actions and maintaining regulatory registrations, quality systems and certifications after closing, subject to the agreed transition arrangements and allocation of costs and liabilities. We may also bear liabilities for certain claims relating to products sold before closing. Product failures, recalls, adverse inspection findings or loss of certifications could harm patients, interrupt sales, result in liability that exceeds our insurance and damage our reputation.

We will not acquire all intellectual property used in the acquired business and will depend on continuing licenses and other rights from Vantive.

Certain intellectual property used in the acquired business will remain owned by Vantive or its affiliates. The Purchase Agreement provides us with continuing rights to specified retained intellectual property, including a perpetual, royalty-free license to specified retained intellectual property for uses relating to the acquired business, as well as transitional and other rights relating to specified trademarks and patents. Notwithstanding these protections, our ability to operate and develop the acquired business may depend on intellectual property, technical information, manufacturing know-how and other rights owned or controlled by Vantive or third parties. Limitations on those rights, or our inability to obtain their full benefit, could increase our costs or disrupt manufacturing and other operations.

Integrating the acquired workforce may be more difficult or expensive than anticipated and may limit our flexibility following closing.

The Vantive Transaction will materially expand our international workforce and result in the transfer or hiring of employees in jurisdictions with different employment, consultation, benefits and termination requirements. The Purchase Agreement also requires us to provide specified compensation and benefit arrangements for transferred employees during specified periods following closing, subject to applicable law and collective bargaining requirements. We may incur higher-than-anticipated compensation, benefit, restructuring, retention, severance or other employment costs, and difficulties retaining or recruiting employees with necessary expertise could adversely affect our integration and operation of the acquired business.

The issuance of shares upon conversion of the convertible note could result in substantial dilution to our stockholders, and the convertible note will remain outstanding if required stockholder approval is not obtained.

As part of the consideration for the Vantive Transaction, we will issue to an affiliate of Vantive a $25 million convertible note that will be convertible at the holder’s option at any time into shares of our common stock at an initial conversion price of $14.94 per share, subject to adjustment, and that will bear interest at 3.0% per annum payable in kind by addition to principal. The conversion price increases on the same basis as ordinary PIK interest, so that such interest does not itself increase the shares issuable in respect of the original principal. Until our stockholders approve the issuance under Nasdaq rules, issuances upon conversion, together with other issuances required to be aggregated, may not exceed 19.99% of either the shares of common stock or voting power outstanding immediately before execution of the Purchase Agreement, to the extent the cap is required by Nasdaq rules. The note requires us to seek approval at stockholder meetings subject to specified timing and eligibility provisions, to resubmit the proposal at subsequent annual meetings if approval is not obtained and, in specified circumstances, to hold a special meeting at the holder’s request. Stockholder approval is not a condition to completion of the Vantive Transaction. If approval is not obtained and the exchange cap prevents conversion, the applicable principal and accrued and unpaid interest will remain outstanding and continue to accrue interest in accordance with the convertible note. Conversion of the note would materially dilute existing stockholders and could result in an affiliate of Vantive becoming a significant stockholder. We have also agreed to use commercially reasonable efforts to register the shares issuable upon conversion for resale within the timeframe specified in the note, and the existence of the convertible note and the potential issuance or resale of those shares could adversely affect the market price of our common stock.

The contingent consideration payable in connection with the Vantive Transaction could materially increase the ultimate cost of the transaction and affect our liquidity and flexibility in pursuing future strategic transactions.

In addition to the $125 million base purchase price, the Purchase Agreement provides for up to $45 million of contingent consideration, including EBITDA-based payments of up to $25 million in the aggregate and two potential $10 million revenue-based payments, subject to the terms and calculation provisions of the Purchase Agreement. Amounts that are earned but not immediately payable under specified annual limitations may roll forward, and specified unpaid amounts accrue interest that is payable in cash on demand and is not counted toward the $45 million maximum. If we undergo a change of control or sell 50% or more of our assets during the earnout period, we must either pay the unpaid balance of the $45 million maximum or pay all earned amounts and cause the acquirer to assume the earnout obligations, and the term loans must be prepaid upon a change of control, which may make us a less attractive acquisition target or reduce the price an acquirer would pay. These obligations could reduce cash available to operate our business, repay indebtedness or make investments and could affect the economics, timing or structure of future strategic transactions. Changes to the acquired business or dispositions that materially reduce the contractually defined revenue or EBITDA may also require reductions to the earnout thresholds, so reducing the business’s scope does not necessarily eliminate the earnout exposure.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
In connection with the Company’s reverse stock split effected in July 2026, stockholders who otherwise would have been entitled to receive fractional shares received cash in lieu of such fractional shares. The following table provides information regarding the fractional shares purchased by the Company in connection with the reverse stock split:

PeriodTotal Number of Shares Purchased (1)Average Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsMaximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs
July 1-July 31, 202661$5.51 — — 
August 1-31, 2026— $— — — 
September 1-30, 2026— $— — — 
Total61$5.51 — — 
(1) Represents fractional shares of the Company’s common stock purchased for cash in connection with the Company’s reverse stock split effected in July 2026. These purchases were not made pursuant to a publicly announced repurchase plan or program.
Item 3. Defaults Upon Senior Securities.
20


None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
During the three months ended September 30, 2026, none of our directors or officers, as defined in Rule 16a-1(f)
under the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading
arrangement,” as those terms are defined in Item 408 of Regulation S-K.
Item 6. Exhibits

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
Exhibit No.Description
2.1*†
Equity and Asset Purchase Agreement, dated as of November 2, 2026, by and between Vantive Limited and Rockwell Medical, Inc.
31.1*
Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
31.2*
Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
32.1**
Certification pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) of the Securities Exchange Act of 1934
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema
101.CAL*XBRL Taxonomy Extension Calculation Linkbase
101.DEF*XBRL Taxonomy Extension Definition Database
101.LAB*XBRL Taxonomy Extension Label Linkbase
101.PRE*XBRL Taxonomy Extension Presentation Linkbase
104*
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, formatted in Inline XBRL (included as Exhibit 101)
*Filed herewith
**Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act
†Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request.
21


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ROCKWELL MEDICAL, INC.
(Registrant)
Date: November 12, 2026/s/ Mark Strobeck, Ph.D.
Mark Strobeck, Ph.D. President, Chief Executive Officer and Director
(Principal Executive Officer)
/s/ Jesse Neri
Jesse Neri
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
22

Keep reading